{
    "title": "Hypercalcemia overview",
    "slug": "hypercalcemia-overview",
    "aliases": [
        "/Hypercalcemia+overview",
        "/241"
    ],
    "tiki_page_id": 241,
    "date": "2010-05-13",
    "categories": [
        "Cancer",
        "Interactions"
    ],
    "tags": [
        "Cancer",
        "Interactions",
        "autoimmune",
        "bone",
        "bone cancer",
        "breast cancer",
        "cancer",
        "child",
        "childhood cancer",
        "cognitive",
        "delirium",
        "depression",
        "dialysis",
        "dosage",
        "falls fractures",
        "headache",
        "hemodialysis",
        "high dose",
        "hypertension",
        "intervention",
        "kidney",
        "leukemia",
        "life span",
        "lymphoma",
        "magnesium",
        "magnesium and cancer",
        "metabolic",
        "mood disorders",
        "mortality",
        "multiple myeloma",
        "ovarian cancer",
        "pain",
        "pediatric autoimmune",
        "rheumatoid arthritis",
        "therapeutic intervention",
        "vitamin d"
    ]
}


<table width="771" cellspacing="0" cellpadding="0" border="0"><tbody><tr><td width="100%" valign="top">

<table width="571" cellspacing="0" cellpadding="0" border="0"><tbody><tr><td valign="top"><span class="page-title">Table of Contents<br /><span style="color:rgb(255,0,0);">Downloaded from National Cancer Institute May 2010 - unknown date</span><br />

http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages</span>

<p><a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Section_170">Purpose  of This PDQ Summary</a><br /><a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Section_1">Overview</a><br /></p><table width="100%" cellspacing="0" cellpadding="0" border="0"><tbody><tr><td><img src="http://www.cancer.gov/images/spacer.gif" alt="image" width="30" height="1"></td>

<td width="100%"><a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Section_3">Normal  Calcium Homeostasis</a><br />

<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Section_136">Hormonal  influences </a><br />

<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Section_137">Renal  function</a><br />

<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Section_138">Bone  resorption</a><br /><a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Section_11">Mechanisms  of Cancer-associated Hypercalcemia</a><br /><a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Section_15">Potentiating  Factors</a></td>

</tr></tbody></table><a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Section_19">Incidence  by Cancer Type</a><br /><a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Section_23">Manifestations</a><br /><table width="100%" cellspacing="0" cellpadding="0" border="0"><tbody><tr><td><img src="http://www.cancer.gov/images/spacer.gif" alt="image" width="30" height="1"></td>

<td width="100%"><a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Section_30">Neurologic  Symptoms</a><br /><a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Section_32">Cardiovascular  Symptoms</a><br /><a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Section_34">Gastrointestinal  Symptoms</a><br /><a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Section_36">Renal  Symptoms</a><br /><a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Section_39">Bone  Symptoms</a></td>

</tr></tbody></table><a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Section_41">Assessment</a><br /><table width="100%" cellspacing="0" cellpadding="0" border="0"><tbody><tr><td><img src="http://www.cancer.gov/images/spacer.gif" alt="image" width="30" height="1"></td>

<td width="100%"><a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Section_42">Laboratory  Assessment</a><br />

<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Section_139">Laboratory  studies</a><br /><a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Section_51">Patient  assessment</a><br /><a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Section_57">Decision  to Treat Hypercalcemia</a></td>

</tr></tbody></table><a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Section_59">Management</a><br /><table width="100%" cellspacing="0" cellpadding="0" border="0"><tbody><tr><td><img src="http://www.cancer.gov/images/spacer.gif" alt="image" width="30" height="1"></td>

<td width="100%"><a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Section_60">Prevention</a><br /><a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Section_63">Managing  Hypercalcemia</a><br /><a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Section_69">Mild  Hypercalcemia</a><br /><a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Section_73">Moderate  to Severe Hypercalcemia</a><br /><a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Section_78">Pharmacologic  Inhibition of Osteoclastic Bone Resorption</a><br />

<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Section_142">Bisphosphonates</a><br />

<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Section_143">Calcitonin </a><br />

<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Section_144">Plicamycin</a><br />

<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Section_145">Gallium  nitrate</a><br /><a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Section_94">Other  Therapeutics for Hypercalcemia</a><br />

<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Section_146">Glucocorticoids</a><br />

<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Section_147">Phosphate </a><br />

<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Section_148">Dialysis</a><br />

<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Section_149">Prostaglandin  synthesis Inhibitors </a><br />

<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Section_150">Cisplatin</a><br /><a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Section_107">Patient  and Family Education</a><br /><a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Section_109">Supportive  Care</a><br /><a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Section_151">Psychosocial  Management</a><br />

<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Section_115">Management  of hypercalcemia </a><br /><a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Section_134">Prognosis</a></td>

</tr></tbody></table><a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Section_TopTrialSearch_sid_7">Current  Clinical Trials</a><br /><a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Section_GetMore_3">Get  More Information From NCI</a><br /><a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Section_161">Changes  to This Summary (04/13/2010)</a><br /><a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Section_ContactUs_2">Questions  or Comments About This Summary</a><br /><a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Section_ForMoreInfo_14">More  Information</a>

<p><span class="page-title"><a></a>Purpose of This PDQ Summary</span></p>

<p><a></a>   <a></a></p>

<p>This PDQ cancer information summary provides  comprehensive, peer-reviewed information for health professionals about  the pathophysiology and treatment of hypercalcemia.  This information is  reviewed regularly and updated as necessary by the <a class="Protocol-ExternalRef" href="http://www.cancer.gov/cancerinfo/pdq/supportive-care-board">PDQ  Supportive and Palliative Care Editorial Board</a>.</p>

<a></a>

<p>Information about the following is included in this  summary:</p>

<a></a>   <a></a>

<ul class="Protocol-UL"><li class="Protocol-IL-Bullet">Etiology.</li>

<li class="Protocol-IL-Bullet">Assessment.</li>

<li class="Protocol-IL-Bullet">Management.</li>

</ul><a></a>   <a></a>

<p>This summary is intended as a resource to inform and  assist clinicians and other health professionals who care for cancer  patients during and after cancer treatment.  It does not provide formal  guidelines or recommendations for making health care decisions.   Information in this summary should not be used as a basis for  reimbursement determinations.</p>

<a></a>

<p>Some of the reference citations in this summary are  accompanied by a level-of-evidence designation. These designations are  intended to help readers assess the strength of the evidence supporting  the use of specific interventions or approaches. The PDQ Supportive and  Palliative Care Editorial Board uses a <a class="SummaryRef" href="http://www.cancer.gov/cancertopics/pdq/levels-evidence-supportive-care/HealthProfessional">formal  evidence ranking system</a> in developing its level-of-evidence  designations. The levels focus primarily on the strength of a study's  design as appropriate to the questions being investigated.  These levels  should be easily understood by health professionals and serve as a  starting point for discussing the strength of study results.  These  classifications should not be used as a basis for reimbursement  determinations.</p>

<a></a>

<p>This summary is also available in a <a class="SummaryRef" href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/Patient">patient  version</a>, which is written in less technical language, and in <a class="SummaryRef" href="http://www.cancer.gov/espanol/pdq/cuidados-medicos-apoyo/hipercalcemia/HealthProfessional">Spanish</a>.</p>

<p><a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#top" class="backtotop-link"><img src="http://www.cancer.gov/images/backtotop_red.gif" alt="Back" width="13" height="14">Back to Top</a></p>

<p><span class="page-title"><a></a>Overview</span></p>

<p><a></a>   <a></a></p>

<p>Hypercalcemia is the most common life-threatening  metabolic disorder associated with neoplastic diseases, occurring in an estimated 10% to 20% of all  adults with cancer. It also occurs in children with cancer, but with much less  frequency (approximately 0.5%–1%).[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference2.1">1</a>-<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference2.3">3</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference2.1">1</a>-<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference2.3">3</a>)  Solid tumors (such as lung or breast cancer tumors) as well as certain hematologic malignancies (particularly multiple myeloma) are most  frequently associated with hypercalcemia.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference2.4">4</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference2.4">4</a>)   Although early diagnosis followed by hydration and treatment with agents that decrease serum calcium  concentrations (hypocalcemic drugs) can produce symptomatic improvements within a few  days, diagnosis may be complicated because symptoms may be insidious at onset  and can be confused with those of many malignant and nonmalignant diseases.   However, diagnosis and timely interventions not only are lifesaving in the short term but also may enhance the patient’s  compliance with primary and supportive treatments and may improve quality of life.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference2.5">5</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference2.5">5</a>)    When a patient has a refractory, widely disseminated malignancy for  which specific therapy is no longer being pursued, the patient may want to  consider withholding therapy for hypercalcemia.  For patients or families who  have expressed their wishes regarding end-of-life issues, this may represent a preferred timing and/or mode of death (as compared with a more prolonged  death from advancing metastatic disease).  This option is best considered long  before the onset of severe hypercalcemia or other metabolic abnormalities that  impair cognition, so that the patient may be involved in the decision making.</p>

<a></a>   <span class="Summary-SummarySection-Title-Level2">Normal Calcium  Homeostasis</span><br /><br /><a></a>   <span class="Summary-SummarySection-Title-Level3">Hormonal influences </span>   <a></a>

<p>Calcium homeostasis is maintained by two hormones,  parathormone (parathyroid hormone or PTH) and calcitriol (1,25-dihydroxy vitamin D).   Minute-to-minute regulation of serum-ionized calcium is regulated by PTH.  PTH secretion  is stimulated when ambient serum-ionized calcium is decreased.  PTH acts on peripheral target cell receptors, increasing the efficiency of renal  tubular calcium reabsorption.  In addition, PTH enhances calcium resorption from mineralized bone and stimulates conversion of vitamin D to its active  form, calcitriol, which subsequently increases intestinal absorption of  calcium and phosphorus.  Pharmacologic doses of calcitonin act as an antagonist to  PTH, lowering serum calcium and phosphorus and inhibiting bone reabsorption.</p>

<a></a>   <a></a>   <span class="Summary-SummarySection-Title-Level3">Renal function</span>   <a></a>

<p>Normal, healthy kidneys are capable of filtering large  amounts of calcium, which is subsequently reclaimed by tubular reabsorption.  The kidneys are  capable of increasing calcium excretion nearly fivefold to maintain homeostatic  serum calcium concentrations.  Hypercalcemia may occur, however, when the concentration of calcium present in the extracellular fluid overwhelms  the kidneys’ compensatory mechanisms.</p>

<a></a>

<p>Although calcium reabsorption is linked to sodium and  fluid reabsorption in the proximal renal tubules, fine regulation occurs in the distal renal  tubules primarily under the influence of PTH.  Tumors that are capable of  producing a substance similar to normal PTH such as PTH-related peptide (refer to  the <a class="SummaryRef" href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/HealthProfessional/11.cdr#Section_11">Mechanisms  of Cancer-associated Hypercalcemia</a> section of this summary) drive the  renal tubules to increase calcium reabsorption.  Under these circumstances, hypercalcemia and high calcium concentrations in urine (hypercalciuria) impair sodium and water reabsorption, causing polyuria (a calcium diuresis) with subsequent loss  of circulating fluid volume (dehydration).  As a consequence of  dehydration, renal blood flow and the glomerular filtration rate decrease and proximal  tubular calcium and sodium reabsorption increase, leading to further increases  in serum calcium concentrations.  Anorexia, nausea, and vomiting associated with loss of circulating fluid volume exacerbate dehydration.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference2.6">6</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference2.6">6</a>)   Immobilization caused by weakness and lethargy may exacerbate calcium resorption from  bone. The kidneys may be irreversibly compromised if the concentration of  calcium in the glomerular filtrate exceeds its solubility, resulting in calcium precipitation in the renal tubules (nephrocalcinosis).</p>

<a></a>   <a></a>   <span class="Summary-SummarySection-Title-Level3">Bone resorption</span>   <a></a>

<p>In healthy adults before midlife, bone formation and  resorption are in dynamic balance primarily through the activity of osteoblasts (bone-forming  cells) and osteoclasts (bone-reabsorbing cells).  Even though 99% of total body  calcium is contained in bone, bone seems to have a minor function in the daily  maintenance of plasma calcium levels.  The normal daily exchange between bone and extracellular fluid is quite small.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference2.7">7</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference2.7">7</a>)</p>

<a></a>   <a></a>   <a></a>   <span class="Summary-SummarySection-Title-Level2">Mechanisms of  Cancer-associated Hypercalcemia</span>   <a></a>

<p>The fundamental cause of cancer-induced hypercalcemia is  increased bone resorption with calcium mobilization into the extracellular fluid and, secondarily, inadequate renal calcium clearance.  Two types of  cancer-induced hypercalcemia have been described: osteolytic hypercalcemia and humoral  hypercalcemia.  Osteolytic hypercalcemia results from direct bone destruction by primary  or metastatic tumor.  Humoral hypercalcemia is mediated by circulating  factors secreted by malignant cells without evidence of bony disease.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference2.8">8</a>,<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference2.9">9</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference2.8">8</a>,<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference2.9">9</a>)   It is believed that hypercalcemia results from the release of factors  by malignant cells that ultimately cause calcium reabsorption from bone.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference2.4">4</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference2.4">4</a>)</p>

<a></a>

<p>One such factor is a PTH-like protein known as  parathyroid hormone–related protein or peptide (PTHrP).  PTHrP is a primitive protein that appears  to have important roles in calcium transport and developmental biology.  It  shares partial amino acid sequence and conformational homology with normal PTH;  binds with the same receptors on skeletal and renal target tissues; and  affects calcium and phosphate homeostasis, as does PTH.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference2.9">9</a>-<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference2.11">11</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference2.9">9</a>-<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference2.11">11</a>)   Increased blood levels of PTHrP have been found in patients with solid tumors but not in patients  with hematologic malignancies who develop hypercalcemia.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference2.4">4</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference2.4">4</a>)</p>

<a></a>

<p>Circulating growth factors may also mediate  hypercalcemia.  Potential mediators include transforming growth factor-alpha and -beta, interleukin-1 and  -6, and tumor necrosis factor (TNF)-alpha and -beta.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference2.12">12</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference2.12">12</a>)</p>

<a></a>   <a></a>   <span class="Summary-SummarySection-Title-Level2">Potentiating Factors</span>   <a></a>

<p>Immobility is associated with an increase in resorption  of calcium from bone. Dehydration, anorexia, nausea, and vomiting that exacerbate dehydration  reduce renal calcium excretion.</p>

<a></a>

<p>Hormonal therapy (estrogens, antiestrogens, androgens,  and progestins) may precipitate hypercalcemia.  Thiazide diuretics increase renal calcium reabsorption and may precipitate or exacerbate hypercalcemia.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference2.13">13</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference2.13">13</a>)</p>

<a></a>

<p>Hematologic malignancies may stimulate osteoclastic bone  resorption through the production of cytokines such as TNF-alpha and -beta and interleukin-1  and -6, formerly referred to as osteoclast-activating factor(s).[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference2.7">7</a>,<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference2.9">9</a>,<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference2.14">14</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference2.7">7</a>,<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference2.9">9</a>,<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference2.14">14</a>)</p>

<a></a>   <a></a>

<p><span class="Summary-ReferenceSection"> 						References 					</span></p>

<ol><li><a></a>McKay C, Furman WL: Hypercalcemia  complicating childhood malignancies. Cancer 72 (1): 256-60, 1993.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8508415&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Leblanc A, Caillaud JM, Hartmann O,  et al.: Hypercalcemia preferentially occurs in unusual forms of  childhood non-Hodgkin's lymphoma, rhabdomyosarcoma, and Wilms' tumor. A  study of 11 cases. Cancer 54 (10): 2132-6, 1984.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6091859&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Kerdudo C, Aerts I, Fattet S, et al.:  Hypercalcemia and childhood cancer: a 7-year experience. J Pediatr  Hematol Oncol 27 (1): 23-7, 2005.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15654274&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Warrell RP Jr: Metabolic emergencies.  In: DeVita VT Jr, Hellman S, Rosenberg SA, eds.: Cancer: Principles and  Practice of Oncology. 5th ed. Philadelphia, Pa: Lippincott-Raven  Publishers, 1997, pp 2486-93.  			<br />

</li>

<li><a></a>Theriault RL: Hypercalcemia of  malignancy: pathophysiology and implications for treatment. Oncology  (Huntingt) 7 (1): 47-50; discussion 52-5, 1993.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8420542&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Mundy GR, Ibbotson KJ, D'Souza SM, et  al.: The hypercalcemia of cancer. Clinical implications and pathogenic  mechanisms. N Engl J Med 310 (26): 1718-27, 1984.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6328302&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Mundy GR: Pathophysiology of  cancer-associated hypercalcemia. Semin Oncol 17 (2 Suppl 5): 10-5,  1990.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2185548&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Mundy GR, Martin TJ: The  hypercalcemia of malignancy: pathogenesis and management. Metabolism 31  (12): 1247-77, 1982.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6755168&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Broadus AE, Mangin M, Ikeda K, et  al.: Humoral hypercalcemia of cancer. Identification of a novel  parathyroid hormone-like peptide. N Engl J Med 319 (9): 556-63, 1988.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3043221&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Horiuchi N, Caulfield MP, Fisher JE,  et al.: Similarity of synthetic peptide from human tumor to parathyroid  hormone in vivo and in vitro. Science 238 (4833): 1566-8, 1987.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3685994&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Suva LJ, Winslow GA, Wettenhall RE,  et al.: A parathyroid hormone-related protein implicated in malignant  hypercalcemia: cloning and expression. Science 237 (4817): 893-6, 1987.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3616618&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Dodwell DJ: Malignant bone  resorption: cellular and biochemical mechanisms. Ann Oncol 3 (4):  257-67, 1992.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1390303&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Coleman RE: Bisphosphonate treatment  of bone metastases and hypercalcemia of malignancy. Oncology (Huntingt)  5 (8): 55-60; discussion 60-2, 65, 1991.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1834153&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Warrell RP Jr: Etiology and current  management of cancer-related hypercalcemia. Oncology (Huntingt) 6 (10):  37-43; discussion 43, 47-50, 1992.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1390013&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

</ol><a></a>

<p><a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#top" class="backtotop-link"><img src="http://www.cancer.gov/images/backtotop_red.gif" alt="Back" width="13" height="14">Back to Top</a></p>

<p><span class="page-title"><a></a>Incidence by Cancer Type</span></p>

<p><a></a>   <a></a></p>

<p>Hypercalcemia occurs more frequently in some  malignancies (e.g., squamous cell cancers of the lung, head, neck, and esophagus) than in others.  Within  each disease type, the incidence of hypercalcemia varies greatly in reported  series.  The frequency of hypercalcemia in some of the commonly involved  neoplastic disorders is shown in Table 1.</p>

<a></a>     <a></a>

<p><span class="Summary-Table-Caption">           <b>Table 1. Incidence of Hypercalcemia by Tumor Type<sup>a</sup></b>         </span></p>

<div align="right"><a class="SummaryRef" href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/HealthProfessional/Table1">Enlarge</a></div>

<table width="100%" cellspacing="0" cellpadding="5" border="1" frame="border"><colgroup><col width="2*" /><col width="2*" /></colgroup><thead><tr class="Summary-Table-Head"><td valign="middle" align="center" colspan="1" class="Summary-SummarySection-Small"><b>Tumor Type</b> </td>

<td valign="middle" align="center" colspan="1" class="Summary-SummarySection-Small"><b>Percentage of Patients                                         Who Develop Hypercalcemia</b> </td>

</tr></thead><tfoot><tr><td valign="top" align="left" colspan="2" class="Summary-SummarySection-Small"><i>                 <sup>a</sup>Adapted from Lang-Kummer.[<a class="SummarySection-Table-Small" href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference3.1">1</a>](<a%20class="SummarySection-Table-Small"%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference3.1">1</a>) </i></td>

</tr></tfoot><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1" class="Summary-SummarySection-Small">Lung</td>

<td valign="top" align="left" rowspan="1" colspan="1" class="Summary-SummarySection-Small">27.3</td>

</tr><tr><td valign="top" align="left" rowspan="1" colspan="1" class="Summary-SummarySection-Small">Breast</td>

<td valign="top" align="left" rowspan="1" colspan="1" class="Summary-SummarySection-Small">25.7</td>

</tr><tr><td valign="top" align="left" rowspan="1" colspan="1" class="Summary-SummarySection-Small">Multiple  myeloma</td>

<td valign="top" align="left" rowspan="1" colspan="1" class="Summary-SummarySection-Small">7.3</td>

</tr><tr><td valign="top" align="left" rowspan="1" colspan="1" class="Summary-SummarySection-Small">Head and  neck</td>

<td valign="top" align="left" rowspan="1" colspan="1" class="Summary-SummarySection-Small">6.9</td>

</tr><tr><td valign="top" align="left" rowspan="1" colspan="1" class="Summary-SummarySection-Small">Unknown  primary</td>

<td valign="top" align="left" rowspan="1" colspan="1" class="Summary-SummarySection-Small">4.7</td>

</tr><tr><td valign="top" align="left" rowspan="1" colspan="1" class="Summary-SummarySection-Small">Lymphoma/leukemia</td>

<td valign="top" align="left" rowspan="1" colspan="1" class="Summary-SummarySection-Small">4.3</td>

</tr><tr><td valign="top" align="left" rowspan="1" colspan="1" class="Summary-SummarySection-Small">Renal</td>

<td valign="top" align="left" rowspan="1" colspan="1" class="Summary-SummarySection-Small">4.3</td>

</tr><tr><td valign="top" align="left" rowspan="1" colspan="1" class="Summary-SummarySection-Small">Gastrointestinal</td>

<td valign="top" align="left" rowspan="1" colspan="1" class="Summary-SummarySection-Small">4.1</td>

</tr></tbody></table><br /><a></a>      <a></a>

<p><span class="Summary-ReferenceSection"> 						References 					</span></p>

<ol><li><a></a>Lang-Kummer J: Hypercalcemia. In:  Groenwald SL, Goodman M, Frogge MH, et al., eds.: Cancer Nursing:  Principles and Practice. 4th ed. Sudbury, Mass: Jones and Bartlett  Publishers, 1997, pp 684-701.  			<br />

</li>

</ol><a></a>

<p><a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#top" class="backtotop-link"><img src="http://www.cancer.gov/images/backtotop_red.gif" alt="Back" width="13" height="14">Back to Top</a></p>

<p><span class="page-title"><a></a>Manifestations</span></p>

<p><a></a>   <a></a></p>

<p>There is little correlation between the presenting  symptoms of hypercalcemia and serum calcium concentrations.  Rapid diagnosis of hypercalcemia may  be complicated because symptoms associated with hypercalcemia are characteristically nonspecific and are easily attributed to chronic or  terminal illness.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference4.1">1</a>,<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference4.2">2</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference4.1">1</a>,<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference4.2">2</a>)   Symptom severity may be caused in part by confounding factors such as previous cancer treatment, drug disease-state interactions, or  comorbid pathologies.</p>

<a></a>

<p>Few patients experience all the symptoms that have been  associated with hypercalcemia (see Table 2), and some patients may not experience any  symptoms.  Patients with corrected total serum calcium concentrations higher than  14 mg/dL (>7.0 mEq/L or 3.49 mmol/L) are generally symptomatic.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference4.1">1</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference4.1">1</a>)   It must be emphasized that clinical manifestations are closely related to the  rapidity of hypercalcemia onset.  Some patients develop signs and symptoms when  calcium is only slightly elevated, while others with long-standing hypercalcemia  may tolerate serum calcium levels higher than 13 mg/dL (>6.5 mEq/L or  3.24 mmol/L) with few symptoms.  Neuromuscular manifestations are generally more  marked in older patients than in young patients.</p>

<a></a>

<p>One author observed that malaise and fatigue were the  most common complaints at patient presentation, followed by (in order of decreasing prevalence  rate) varying degrees of obtundation, anorexia, pain, polyuria-polydipsia, constipation, nausea, and vomiting.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference4.3">3</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference4.3">3</a>)</p>

<a></a>     <a></a>

<p><span class="Summary-Table-Caption">           <b>Table 2. Symptom Prevalence Among Patients Treated for  Hypercalcemia            of Malignancy Stratified by Corrected Serum Total Calcium            Concentrations at Presentation<sup>a</sup></b>         </span></p>

<div align="right"><a class="SummaryRef" href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/HealthProfessional/Table2">Enlarge</a></div>

<table width="100%" cellspacing="0" cellpadding="5" border="1" frame="border"><colgroup><col width="*" /><col width="*" /><col width="*" /></colgroup><thead><tr class="Summary-Table-Head"><td valign="middle" align="center" colspan="1" class="Summary-SummarySection-Small"><b>Symptoms</b> </td>

<td valign="middle" align="center" colspan="2" class="Summary-SummarySection-Small"><b>Prevalence (%) by Serum Calcium            Concentration</b> </td>

</tr></thead><tfoot><tr><td valign="top" align="left" colspan="3" class="Summary-SummarySection-Small"><i>                 <sup>a</sup>Adapted from Ralston et al.[<a class="SummarySection-Table-Small" href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference4.3">3</a>](<a%20class="SummarySection-Table-Small"%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference4.3">3</a>)</i></td>

</tr></tfoot><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1" class="Summary-SummarySection-Small"> </td>

<td valign="top" align="left" rowspan="1" colspan="1" class="Summary-SummarySection-Small"><b><3.5 mmol/L</b></td>

<td valign="top" align="left" rowspan="1" colspan="1" class="Summary-SummarySection-Small"><b>?3.5 mmol/L</b></td>

</tr><tr><td valign="top" align="left" rowspan="1" colspan="1" class="Summary-SummarySection-Small">Central  nervous system symptoms</td>

<td valign="top" align="left" rowspan="1" colspan="1" class="Summary-SummarySection-Small">41</td>

<td valign="top" align="left" rowspan="1" colspan="1" class="Summary-SummarySection-Small">80</td>

</tr><tr><td valign="top" align="left" rowspan="1" colspan="1" class="Summary-SummarySection-Small">Constipation</td>

<td valign="top" align="left" rowspan="1" colspan="1" class="Summary-SummarySection-Small">21</td>

<td valign="top" align="left" rowspan="1" colspan="1" class="Summary-SummarySection-Small">25</td>

</tr><tr><td valign="top" align="left" rowspan="1" colspan="1" class="Summary-SummarySection-Small">Malaise-fatigue</td>

<td valign="top" align="left" rowspan="1" colspan="1" class="Summary-SummarySection-Small">65</td>

<td valign="top" align="left" rowspan="1" colspan="1" class="Summary-SummarySection-Small">50</td>

</tr><tr><td valign="top" align="left" rowspan="1" colspan="1" class="Summary-SummarySection-Small">Anorexia</td>

<td valign="top" align="left" rowspan="1" colspan="1" class="Summary-SummarySection-Small">47</td>

<td valign="top" align="left" rowspan="1" colspan="1" class="Summary-SummarySection-Small">59</td>

</tr><tr><td valign="top" align="left" rowspan="1" colspan="1" class="Summary-SummarySection-Small">Nausea  and/or vomiting</td>

<td valign="top" align="left" rowspan="1" colspan="1" class="Summary-SummarySection-Small">22</td>

<td valign="top" align="left" rowspan="1" colspan="1" class="Summary-SummarySection-Small">30</td>

</tr><tr><td valign="top" align="left" rowspan="1" colspan="1" class="Summary-SummarySection-Small">Polyuria  and/or polydipsia</td>

<td valign="top" align="left" rowspan="1" colspan="1" class="Summary-SummarySection-Small">34</td>

<td valign="top" align="left" rowspan="1" colspan="1" class="Summary-SummarySection-Small">35</td>

</tr><tr><td valign="top" align="left" rowspan="1" colspan="1" class="Summary-SummarySection-Small">Pain</td>

<td valign="top" align="left" rowspan="1" colspan="1" class="Summary-SummarySection-Small">51</td>

<td valign="top" align="left" rowspan="1" colspan="1" class="Summary-SummarySection-Small">35</td>

</tr></tbody></table><br /><a></a>      <a></a>

<p>Clinical manifestations can be categorized according  to body systems and functions.</p>

<a></a>   <span class="Summary-SummarySection-Title-Level2">Neurologic Symptoms</span>   <a></a>

<p>Calcium ions have a major role in neurotransmission.   Increased calcium levels decrease neuromuscular excitability, which leads to hypotonicity in  smooth and striated muscle.  Symptom severity correlates directly with the  magnitude of serum-ionized calcium concentrations and inversely with their rate of  change.  Neuromuscular symptoms include weakness and diminished deep-tendon  reflexes.  Muscle strength is impaired, and respiratory muscular capacity may be decreased.  Central nervous system impairment may manifest as delirium  with prominent symptoms of personality change, cognitive dysfunction, disorientation, incoherent speech, and psychotic symptoms such as hallucinations and delusions.  Obtundation is progressive as serum  calcium concentrations increase and may progress to stupor or coma.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference4.1">1</a>,<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference4.2">2</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference4.1">1</a>,<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference4.2">2</a>)   Local neurologic signs are not common, but hypercalcemia has been documented  to increase cerebrospinal fluid protein, which may be associated with  headache.  Headache can be exacerbated by vomiting and dehydration.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference4.2">2</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference4.2">2</a>)   Abnormal electroencephalograms are seen in patients with marked hypercalcemia.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference4.1">1</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference4.1">1</a>)</p>

<a></a>   <a></a>   <span class="Summary-SummarySection-Title-Level2">Cardiovascular  Symptoms</span>   <a></a>

<p>Hypercalcemia is associated with increased myocardial  contractility and irritability.  Electrocardiographic changes are characterized by slowed conduction, including prolonged P-R interval, widened QRS complex,  shortened Q-T interval, shortened or absent S-T segments, and possibly abrupt  sloping and early peaking of the proximal limb of T waves.  Hypercalcemia enhances patients’ sensitivity to the pharmacologic effects of digitalis glycosides (e.g., digoxin).  When serum calcium concentrations exceed 16 mg/dL (>8.0  mEq/L or 3.99 mmol/L), T waves widen, secondarily increasing the Q-T interval.   As calcium concentrations increase, bradyarrhythmias and bundle branch  block may develop.  Incomplete or complete atrioventricular block may develop at  serum concentrations around 18 mg/dL (9.0 mEq/L or 4.49 mmol/L) and may progress to complete  heart block, asystole, and cardiac arrest.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference4.1">1</a>,<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference4.2">2</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference4.1">1</a>,<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference4.2">2</a>)</p>

<a></a>   <a></a>   <span class="Summary-SummarySection-Title-Level2">Gastrointestinal  Symptoms</span>   <a></a>

<p>Gastrointestinal symptoms are probably related to the  depressive action of hypercalcemia on the autonomic nervous system and resulting  smooth-muscle hypotonicity.  Increased gastric acid secretion often accompanies  hypercalcemia and may intensify gastrointestinal manifestations.  Anorexia, nausea,  and vomiting are intensified by increased gastric residual volume.   Constipation is aggravated by dehydration that accompanies hypercalcemia.  Abdominal  pain may progress to obstipation and can be confused with acute abdominal  obstruction.</p>

<a></a>   <a></a>   <span class="Summary-SummarySection-Title-Level2">Renal Symptoms</span>   <a></a>

<p>Hypercalcemia causes a reversible tubular defect in the  kidney, resulting in the loss of urinary concentrating ability and polyuria.  Decreased fluid  intake and polyuria lead to symptoms associated with dehydration, including thirst,  dry mucosa, diminished or absent sweating, poor skin turgor, and  concentrated urine.  Decreased proximal reabsorption of sodium, magnesium, and  potassium occur as a result of salt and water depletion that is caused by cellular dehydration and hypotension.  Renal insufficiency may occur as a result  of diminished glomerular filtration, a complication observed most often in patients with myeloma.</p>

<a></a>

<p>Although nephrolithiasis and nephrocalcinosis are  usually not associated with hypercalcemia of malignancy, calcium phosphate crystals can precipitate  within renal tubules to form renal calculi as a consequence of long-standing hypercalciuria.  When they occur, coexisting primary hyperparathyroidism  should be considered.</p>

<a></a>   <a></a>   <span class="Summary-SummarySection-Title-Level2">Bone Symptoms</span>   <a></a>

<p>Hypercalcemia of malignancy can result from osteolytic  metastases or humerally mediated bone resorption with secondary fractures, skeletal deformities, and pain.</p>

<a></a>   <a></a>

<p><span class="Summary-ReferenceSection"> 						References 					</span></p>

<ol><li><a></a>Bajorunas DR: Clinical manifestations  of cancer-related hypercalcemia. Semin Oncol 17 (2 Suppl 5): 16-25,  1990.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2185549&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Mahon SM: Signs and symptoms  associated with malignancy-induced hypercalcemia. Cancer Nurs 12 (3):  153-60, 1989.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2743297&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Ralston SH, Gallacher SJ, Patel U, et  al.: Cancer-associated hypercalcemia: morbidity and mortality. Clinical  experience in 126 treated patients. Ann Intern Med 112 (7): 499-504,  1990.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2138442&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

</ol><a></a>

<p><a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#top" class="backtotop-link"><img src="http://www.cancer.gov/images/backtotop_red.gif" alt="Back" width="13" height="14">Back to Top</a></p>

<p><span class="page-title"><a></a>Assessment</span></p>

<p><a></a><br /><br /><a></a>   <span class="Summary-SummarySection-Title-Level2">Laboratory  Assessment</span>   <a></a></p>

<p>Normal serum calcium levels are maintained within  narrow and constant limits, approximately 9.0 to 10.3 mg/dL (= 4.5–5.2 mEq/L or 2.25–2.57 mmol/L)  for men and 8.9 to 10.2 mg/dL (= 4.4–5.1 mEq/L or 2.22–2.54 mmol/L) for women.  Symptoms of hypocalcemia or hypercalcemia are caused by abnormalities in  the ionized fraction of the plasma calcium concentration;  however, ionized calcium  levels are rarely checked routinely in clinical laboratories.  The total plasma  calcium is used to infer the ionized calcium fraction and is usually accurate,  except in the setting of hypoalbuminemia.  Because hypoalbuminemia is not uncommon  among patients with cancer, it is necessary to correct the total plasma  calcium concentration for the percent of calcium that would have been measured  if the albumin level were within normal range.  The calculation is as follows:</p>

<a></a>

<p><b>total serum calcium corrected for albumin level:</b> <span>[(normal albumin –  patient’s albumin) × 0.8]</span> + patient’s measured total  calcium</p>

<a></a>

<p>This calculated value is fairly accurate, except in the  presence of elevated serum paraproteins, such as in multiple myeloma.  In this case,  laboratory measurement of the actual ionized calcium concentration may be  necessary.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference5.1">1</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference5.1">1</a>)</p>

<a></a>

<p>Calcium also binds to globulins in blood.  In contrast  with hypoalbuminemia, hypogammaglobulinemia has a relatively small effect on calcium protein  binding.  Serum total calcium concentration can be corrected for changes in  globulins as follows: total serum calcium concentration varies directly by 0.16  mg/dL, 0.08 mEq/L, or 0.04 mmol/L with each 1 g/dL change in globulin concentration.   In clinical practice, changes in serum globulin concentrations rarely  effect clinically significant changes in the ionized calcium fraction.</p>

<a></a>

<p>Acid-base status also affects the interpretation of  serum calcium values.  While acidosis decreases the protein-bound fraction (consequently  increasing the ionized calcium fraction), alkalosis increases protein binding.   Serum total calcium concentration can be corrected for changes in pH as  follows:  total serum calcium concentration varies inversely by 0.12 mg/dL, 0.06  mEq/L, or 0.03 mmol/L with each 0.1 unit change in pH.  Unlike changes in serum albumin concentration, alterations in blood pH rarely effect clinically significant changes in the ionized calcium fraction.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference5.2">2</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference5.2">2</a>)</p>

<a></a>   <span class="Summary-SummarySection-Title-Level3">Laboratory studies</span>   <a></a>   <a></a>

<p>It is important to measure the serum calcium and albumin  concentrations.  Other selected tests (as shown below) may be useful in  some instances:</p>

<a></a>   <a></a>

<ul class="Protocol-UL"><li class="Protocol-IL-Bullet">Blood urea nitrogen and creatinine  concentrations (renal function).</li>

</ul><p> </p>

</td></tr></tbody></table></td></tr></tbody></table>Immunoreactive parathormone  (iPTH):

iPTH  concentration is increased or rarely normal in hyperparathyroid disease.

iPTH is typically decreased  or undetectable in hypercalcemia of malignancy.

<p> </p>

Parathyroid hormone–related  peptide (if available).

<p> </p>

Serum 1,25-dihydroxy vitamin D  concentration in patients with hematologic malignancies.

<p> </p>

Other serum electrolyte  concentrations (phosphate, magnesium).

<p> </p>

<a></a>   <a></a>   <a></a>   <span class="Summary-SummarySection-Title-Level2">Patient assessment</span>   <a></a>

<p>Primary assessment should include the following:[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference5.3">3</a>,<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference5.4">4</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference5.3">3</a>,<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference5.4">4</a>)</p>

<a></a>   <a></a>

<ul class="Protocol-UL"><li class="Protocol-IL-Bullet">History:<a></a><a></a>

<ul class="Protocol-UL"><li class="Protocol-IL-Dash">How rapidly have symptoms developed?  Symptoms of malignancy are usually present when hypercalcemia is caused  by cancer.   Rapid symptom onset is more typical of hypercalcemia of malignancy than hypercalcemia associated with hyperparathyroidism and other diseases.</li>

<li class="Protocol-IL-Dash">Is there radiographic  evidence of primary or metastatic bony disease?</li>

<li class="Protocol-IL-Dash">Has the patient recently  received treatment with tamoxifen or estrogenic  or androgenic steroids?</li>

<li class="Protocol-IL-Dash">Is the patient taking digoxin?</li>

<li class="Protocol-IL-Dash">Is there an exogenous calcium  source such as intravenous fluids or        parenteral nutrition?</li>

<li class="Protocol-IL-Dash">Is the patient receiving  thiazide diuretics, vitamin A, vitamin D, or lithium?</li>

<li class="Protocol-IL-Dash">Is there concurrent disease  predisposing to dehydration or immobility?</li>

<li class="Protocol-IL-Dash">Are there potentially effective  treatments for the patient’s underlying malignancy?</li>

</ul><a></a></li>

</ul><p> </p>

Clinical status (refer to the Manifestations  section of this summary): 

Neuromuscular (evaluate  muscular strength, muscle tone, and decreased deep-tendon reflexes).

Neurologic (fatigue, apathy,  depression, confusion, or restlessness).

Cardiovascular (hypertension,  electrocardiogram changes, arrhythmias, or digitalis toxicity).

Renal (urine output polyuria,  nocturia, glucosuria, or polydipsia).

Gastrointestinal (anorexia, nausea, abdominal  pain, constipation, decreased bowel sounds, or abdominal distention).

Miscellaneous (musculoskeletal  pain or pruritus).

<p> </p>

<a></a>   <a></a>   <a></a>   <span class="Summary-SummarySection-Title-Level2">Decision to Treat  Hypercalcemia</span>   <a></a>

<p>The decision to correct clinical hypercalcemia must be  considered within the context of therapeutic goals as determined by the patient, the  caregivers, and the medical staff.  The natural course of untreated hypercalcemia is  well known to clinicians: As with hepatic or metabolic encephalopathy, untreated hypercalcemia will progress to loss of consciousness and coma.  This  clinical course may be desirable at the end of life in patients with intractable suffering and/or unmanageable symptoms when no further active treatment  is available or desired for reversal of the primary disease process.</p>

<a></a>   <a></a>

<p><span class="Summary-ReferenceSection"> 						References 					</span></p>

<ol><li><a></a>Beers MH, Berkow R, eds.: The Merck  Manual of Diagnosis and Therapy. 17th ed. Whitehouse Station, NJ: Merck  Research Laboratories, 1999.  			<br />

</li>

<li><a></a>Bajorunas DR: Clinical manifestations  of cancer-related hypercalcemia. Semin Oncol 17 (2 Suppl 5): 16-25,  1990.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2185549&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Calafato A, Jessup AL: Body fluid  composition, alteration in: hypercalcemia. In: McNally JC, Somerville  ET, Miaskowski C, et al., eds.: Guidelines for Oncology Nursing  Practice. 2nd ed. Philadelphia, Pa: WB Saunders Company, 1991, pp  397-401.  			<br />

</li>

<li><a></a>Coward DD: Hypercalcemia knowledge  assessment in patients at risk of developing cancer-induced  hypercalcemia. Oncol Nurs Forum 15 (4): 471-6, 1988 Jul-Aug.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3399418&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

</ol><a></a>

<p><a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#top" class="backtotop-link"><img src="http://www.cancer.gov/images/backtotop_red.gif" alt="Back" width="13" height="14">Back to Top</a></p>

<p><span class="page-title"><a></a>Management</span></p>

<p><a></a>   <a></a></p>

<p>Note: Some citations in the text of this section  are followed by a level of evidence. The PDQ Editorial Boards use a  formal ranking system to help the reader judge the strength of evidence  linked to the reported results of a therapeutic strategy. (Refer to the  PDQ summary on <a class="SummaryRef" href="http://www.cancer.gov/cancertopics/pdq/levels-evidence-supportive-care/HealthProfessional">Levels  of Evidence</a> for more information.)</p>

<a></a>   <span class="Summary-SummarySection-Title-Level2">Prevention</span>   <a></a>

<p>Individuals at risk of developing hypercalcemia may be  the first to recognize symptoms such as fatigue.  Patients should be advised about the ways in  which hypercalcemia most frequently manifests itself and should also be given guidelines for seeking professional intervention.  Preventive measures  include ensuring adequate fluid intake of 3 to 4 L (100–140 fl oz per day if not contraindicated) and salt intake, nausea and vomiting control,  encouraging patient mobility, attention to febrile episodes, and cautious use or elimination of drugs that may complicate management.  This includes  drugs that inhibit urinary calcium excretion or decrease renal blood flow, as well  as medications that contain calcium, vitamin D, vitamin A, or other  retinoids.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.1">1</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.1">1</a>)</p>

<a></a>

<p>Even though the gut has a role in normal calcium  homeostasis, absorption is usually diminished in individuals with hypercalcemia, making dietary  calcium restriction unnecessary.</p>

<a></a>   <a></a>   <span class="Summary-SummarySection-Title-Level2">Managing  Hypercalcemia</span>   <a></a>

<p>Symptomatic treatment of hypercalcemia focuses first on  correcting dehydration and enhancing renal calcium excretion, followed by specific hypocalcemic treatment with agents that inhibit bone resorption (e.g., calcitonin, bisphosphonates, gallium nitrate, and plicamycin).[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.2">2</a>,<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.3">3</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.2">2</a>,<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.3">3</a>)   Definitive treatment is that which effectively treats the malignant disease underlying hypercalcemia.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.4">4</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.4">4</a>)   At one time, hypercalcemia was treated with aggressive intravenous hydration using isotonic saline followed by the  administration of a diuretic.  This volume expansion and natriuresis was performed to  increase renal blood flow and enhance calcium excretion.  This approach is not very  effective in correcting hypercalcemia and can lead to complications of fluid  overload.  Intravenous fluid should be administered to correct water loss  associated with calciuresis and dehydration due to vomiting.  Administration of  diuretics should be restricted to balancing urine output in patients who have been adequately rehydrated.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.1">1</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.1">1</a>)</p>

<a></a>

<p>The magnitude of hypercalcemia and the severity of  symptoms typically form the basis for determining whether treatment is indicated.  Immediate  aggressive hypocalcemic treatment is warranted in patients with a corrected total  serum calcium level higher than 14 mg/dL (>7 mEq/L or 3.5 mmol/L).  In  patients with a total corrected serum calcium concentration between 12 and 14 mg/dL (6–7 mEq/L  or 3.0–3.5 mmol/L), clinical manifestations should guide the type of  therapy and the urgency with which it is implemented.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.2">2</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.2">2</a>)   Treatment response is indicated by resolution of symptoms attributable to hypercalcemia and by  diminishing serum calcium concentrations and urinary calcium and hydroxyproline  excretion.</p>

<a></a>

<p>Aggressive treatment is not generally indicated in  patients with mild hypercalcemia (corrected total serum calcium level lower than 12 mg/dL  [<6 mEq/L or 3.0 mmol/L](<6%20mEq/L%20or%203.0%20mmol/L)).  Clear treatment decisions are problematic for patients with  mild hypercalcemia and coexistent central nervous system symptoms, especially  for younger patients in whom hypercalcemia is generally better tolerated.   It is very important to evaluate other causes for altered central nervous  system function before attributing them solely to hypercalcemia.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.2">2</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.2">2</a>)</p>

<a></a>

<p>Treatment can provide marked improvement of distressing  symptoms.  Polyuria, polydipsia, central nervous system symptoms, nausea, vomiting, and  constipation are more likely to be managed successfully than are anorexia, malaise,  and fatigue.  Pain control may be improved for some patients who achieve normocalcemia.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.5">5</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.5">5</a>)[<a>click="javascript:popWindow('defbyid','CDR0000663087&version=HealthProfessional&language=English');                         return(false);" href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663087&version=HealthProfessional&language=English" class="Summary-LOERef">Level of evidence: III</a>](<a>click="javascript:popWindow('defbyid','CDR0000663087&version=HealthProfessional&language=English');%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20return(false);"%20href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663087&version=HealthProfessional&language=English"%20class="Summary-LOERef">Level%20of%20evidence:%20III</a>)  Effective calcium-lowering  therapy usually improves symptoms, enhances the quality of life, and may allow patients to be  managed in a subacute, ambulatory, or home care setting.</p>

<a></a>

<p>After normocalcemia is achieved, serum calcium should be  monitored serially, with the frequency determined by anticipated duration of response to any particular hypocalcemic regimen.</p>

<a></a>   <a></a>   <span class="Summary-SummarySection-Title-Level2">Mild Hypercalcemia</span>   <a></a>

<p>Mild hypercalcemia is defined as corrected total serum  calcium level lower than 12 mg/dL (<6 mEq/L or 3.0 mmol/L).</p>

<a></a>

<p>Hydration followed by observation is a treatment option.   This option should be considered for asymptomatic patients who are about to be treated for  tumors that are likely to respond to antineoplastic treatment (e.g., lymphoma,  breast cancer, ovarian cancer, head and neck carcinoma, and multiple myeloma).[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.6">6</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.6">6</a>)</p>

<a></a>

<p>In symptomatic patients or when tumor response to  therapy is expected to occur slowly, therapy for hypercalcemia should be implemented to manage  symptoms and stabilize patients’ metabolic states.  Additional ancillary  interventions should be directed toward controlling nausea and vomiting, encouraging  mobility, noting febrile episodes, and the minimal use of sedating medications.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.6">6</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.6">6</a>)</p>

<a></a>   <a></a>   <span class="Summary-SummarySection-Title-Level2">Moderate to Severe  Hypercalcemia</span>   <a></a>

<p>Moderate to severe hypercalcemia is defined as corrected  total serum calcium equal to 12 to 14 mg/dL (6–7 mEq/L or 3.0–3.5 mmol/L).</p>

<a></a>

<p>Rehydration is the essential first step in treating  moderate or severe hypercalcemia.  Although fewer than 30% of patients achieve  normocalcemia with hydration alone, replenishing extracellular fluid, restoring  intravascular volume, and saline diuresis are fundamental to initial therapy.   Adequate rehydration may require 3,000 to 6,000 mL of 0.9% sodium chloride for  injection (normal saline) within the first 24 hours to restore fluid volume.   Restoring normal extracellular fluid volume will increase daily urinary calcium  excretion by 100 to 300 mg.  Clinical improvement in mental status and nausea and vomiting is usually apparent within 24 hours for most patients; however, rehydration is a temporizing intervention.  If definitive cytoreductive therapies (surgery, radiation, or chemotherapy) are not forthcoming, hypocalcemic agents must be used to achieve long-term control.</p>

<a></a>

<p>Thiazide diuretics increase renal tubular calcium  absorption and may exacerbate hypercalcemia.  Thus, thiazide diuretics are contraindicated in  hypercalcemia patients.  Loop diuretics (e.g., furosemide, bumetanide, and ethacrynic  acid) induce hypercalciuria by inhibiting calcium reabsorption in the  ascending limb of the loop of Henle, but they should not be administered until fluid  volume is restored.  Otherwise, loop diuretics can exacerbate fluid loss, further reducing calcium clearance.  Because sodium and calcium clearance are  closely linked during osmotic diuresis, loop diuretics will depress the proximal tubular resorptive mechanisms for calcium, increasing calcium excretion  to 400 to 800 mg per day.</p>

<a></a>

<p>Moderate doses of furosemide (20–40 mg every 12 hours)  increase saline-induced urinary calcium excretion and are useful in preventing or managing fluid overload in adequately rehydrated patients.  Aggressive treatment with furosemide (80–100 mg every 2–4 hours) is problematic because it  requires concurrent administration of large volumes of saline to prevent  intravascular dehydration.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.7">7</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.7">7</a>)[<a>click="javascript:popWindow('defbyid','CDR0000663087&version=HealthProfessional&language=English');                         return(false);" href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663087&version=HealthProfessional&language=English" class="Summary-LOERef">Level of evidence: III</a>](<a>click="javascript:popWindow('defbyid','CDR0000663087&version=HealthProfessional&language=English');%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20return(false);"%20href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663087&version=HealthProfessional&language=English"%20class="Summary-LOERef">Level%20of%20evidence:%20III</a>)  This, in turn, requires  intensive hemodynamic monitoring (to avoid volume overload and cardiac decompensation) and frequent serial  measurements of urinary volume and electrolytes (to prevent life-threatening hypophosphatemia, hypokalemia, and hypomagnesemia).[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.6">6</a>,<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.8">8</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.6">6</a>,<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.8">8</a>)[<a>click="javascript:popWindow('defbyid','CDR0000663089&version=HealthProfessional&language=English');                         return(false);" href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663089&version=HealthProfessional&language=English" class="Summary-LOERef">Level of evidence: IV</a>](<a>click="javascript:popWindow('defbyid','CDR0000663089&version=HealthProfessional&language=English');%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20return(false);"%20href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663089&version=HealthProfessional&language=English"%20class="Summary-LOERef">Level%20of%20evidence:%20IV</a>)</p>

<a></a>   <a></a>   <span class="Summary-SummarySection-Title-Level2">Pharmacologic  Inhibition of Osteoclastic Bone Resorption</span>   <a></a>

<p>Described below are therapies that can inhibit  osteoclastic bone resorption.  The most widely used modality for this purpose is a bisphosphonate (such  as pamidronate).  The use of other agents such as calcitonin, mithramycin,  or gallium nitrate is less common.</p>

<a></a>   <span class="Summary-SummarySection-Title-Level3">Bisphosphonates</span>   <a></a>

<p>Bisphosphonates are one of the most effective  pharmacologic alternatives for controlling hypercalcemia.  They bind to hydroxyapatite in calcified  bone, rendering it resistant to hydrolytic dissolution by phosphatases,  thereby inhibiting both normal and abnormal bone resorption.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.9">9</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.9">9</a>)   Bisphosphonate treatment reduces the number of osteoclasts in sites undergoing active  bone resorption and may prevent osteoclast expansion by inhibiting  differentiation from their monocyte-macrophage precursors.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.10">10</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.10">10</a>)[<a>click="javascript:popWindow('defbyid','CDR0000663089&version=HealthProfessional&language=English');                         return(false);" href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663089&version=HealthProfessional&language=English" class="Summary-LOERef">Level of evidence: IV</a>](<a>click="javascript:popWindow('defbyid','CDR0000663089&version=HealthProfessional&language=English');%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20return(false);"%20href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663089&version=HealthProfessional&language=English"%20class="Summary-LOERef">Level%20of%20evidence:%20IV</a>)  Bisphosphonates have  variable effects on other aspects of bone remodeling, such as new bone formation  and mineralization.  For example, etidronate at clinically relevant dosages (300–1,600 mg/day) inhibits new bone formation and mineralization.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.11">11</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.11">11</a>)[<a>click="javascript:popWindow('defbyid','CDR0000663072&version=HealthProfessional&language=English');                         return(false);" href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663072&version=HealthProfessional&language=English" class="Summary-LOERef">Level of evidence: II</a>](<a>click="javascript:popWindow('defbyid','CDR0000663072&version=HealthProfessional&language=English');%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20return(false);"%20href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663072&version=HealthProfessional&language=English"%20class="Summary-LOERef">Level%20of%20evidence:%20II</a>)  With prolonged etidronate use, osteomalacia and pathologic fractures may occur.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.12">12</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.12">12</a>)[<a>click="javascript:popWindow('defbyid','CDR0000663087&version=HealthProfessional&language=English');                         return(false);" href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663087&version=HealthProfessional&language=English" class="Summary-LOERef">Level of evidence: III</a>](<a>click="javascript:popWindow('defbyid','CDR0000663087&version=HealthProfessional&language=English');%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20return(false);"%20href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663087&version=HealthProfessional&language=English"%20class="Summary-LOERef">Level%20of%20evidence:%20III</a>)  In contrast, clodronate,  pamidronate, and alendronate are 10, 100, and 1,000 times more potent inhibitors of bone resorption than  etidronate and are clinically useful at dosages that are less likely to adversely  affect new bone formation and mineralization.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.13">13</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.13">13</a>)[<a>click="javascript:popWindow('defbyid','CDR0000663089&version=HealthProfessional&language=English');                         return(false);" href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663089&version=HealthProfessional&language=English" class="Summary-LOERef">Level of evidence: IV</a>](<a>click="javascript:popWindow('defbyid','CDR0000663089&version=HealthProfessional&language=English');%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20return(false);"%20href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663089&version=HealthProfessional&language=English"%20class="Summary-LOERef">Level%20of%20evidence:%20IV</a>);[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.14">14</a>-<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.16">16</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.14">14</a>-<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.16">16</a>)[<a>click="javascript:popWindow('defbyid','CDR0000663072&version=HealthProfessional&language=English');                         return(false);" href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663072&version=HealthProfessional&language=English" class="Summary-LOERef">Level of evidence: II</a>](<a>click="javascript:popWindow('defbyid','CDR0000663072&version=HealthProfessional&language=English');%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20return(false);"%20href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663072&version=HealthProfessional&language=English"%20class="Summary-LOERef">Level%20of%20evidence:%20II</a>)  Many bisphosphonates may be useful in treating hypercalcemia of malignancy.    In the United States, etidronate and pamidronate are the only bisphosphonates  approved for treating hypercalcemia.</p>

<a></a>

<p>In a randomized double-blind study comparing pamidronate  with etidronate for the treatment of cancer-related hypercalcemia, pamidronate (60 mg  intravenous <span>[IV]</span> single dose over 24 hours) has been demonstrated to be  more effective with respect to serum calcium reduction and duration of  hypocalcemic response than etidronate (7.5 mg/kg of body weight per day administered  over 2 hours as a daily IV infusion for 3 consecutive days).[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.17">17</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.17">17</a>)[<a>click="javascript:popWindow('defbyid','CDR0000663069&version=HealthProfessional&language=English');                         return(false);" href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663069&version=HealthProfessional&language=English" class="Summary-LOERef">Level of evidence: I</a>](<a>click="javascript:popWindow('defbyid','CDR0000663069&version=HealthProfessional&language=English');%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20return(false);"%20href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663069&version=HealthProfessional&language=English"%20class="Summary-LOERef">Level%20of%20evidence:%20I</a>)  This finding has led to the diminished use of etidronate.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.1">1</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.1">1</a>)</p>

<a></a>

<p>In treating moderate hypercalcemia (corrected serum  calcium <13.5 mg/dL, <6.75 mEq/L, or <3.37 mmol/L), pamidronate 60 to 90 mg IV is administered  over 2 to 24 hours.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.18">18</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.18">18</a>)   Onset of pamidronate’s effect is apparent within 3 to 4 days, with maximal effect within 7 to 10 days after commencing  treatment.  The effect may persist for 7 to 30 days.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.19">19</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.19">19</a>)[<a>click="javascript:popWindow('defbyid','CDR0000663069&version=HealthProfessional&language=English');                         return(false);" href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663069&version=HealthProfessional&language=English" class="Summary-LOERef">Level of evidence: I</a>](<a>click="javascript:popWindow('defbyid','CDR0000663069&version=HealthProfessional&language=English');%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20return(false);"%20href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663069&version=HealthProfessional&language=English"%20class="Summary-LOERef">Level%20of%20evidence:%20I</a>)  It is recommended that a minimum of 7 days elapse before re-treatment with pamidronate to assess full response to the initial dose.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.18">18</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.18">18</a>)   Adverse effects include transient low-grade temperature elevations (1°C–2°C) that typically  occur within 24 to 36 hours after administration and persist for up to 2 days  in up to 20% of patients.  Pamidronate has also been used successfully in  children, with similar side effects.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.20">20</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.20">20</a>)[<a>click="javascript:popWindow('defbyid','CDR0000663087&version=HealthProfessional&language=English');                         return(false);" href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663087&version=HealthProfessional&language=English" class="Summary-LOERef">Level of evidence: III</a>](<a>click="javascript:popWindow('defbyid','CDR0000663087&version=HealthProfessional&language=English');%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20return(false);"%20href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663087&version=HealthProfessional&language=English"%20class="Summary-LOERef">Level%20of%20evidence:%20III</a>) Other bisphosphonates  (except clodronate) may also produce transient temperature elevations; the incidence of temperature  elevation, nausea, anorexia, dyspepsia, and vomiting may be increased by rapid administration.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.21">21</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.21">21</a>)[<a>click="javascript:popWindow('defbyid','CDR0000663069&version=HealthProfessional&language=English');                         return(false);" href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663069&version=HealthProfessional&language=English" class="Summary-LOERef">Level of evidence: I</a>](<a>click="javascript:popWindow('defbyid','CDR0000663069&version=HealthProfessional&language=English');%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20return(false);"%20href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663069&version=HealthProfessional&language=English"%20class="Summary-LOERef">Level%20of%20evidence:%20I</a>);[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.22">22</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.22">22</a>)[<a>click="javascript:popWindow('defbyid','CDR0000663087&version=HealthProfessional&language=English');                         return(false);" href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663087&version=HealthProfessional&language=English" class="Summary-LOERef">Level of evidence: III</a>](<a>click="javascript:popWindow('defbyid','CDR0000663087&version=HealthProfessional&language=English');%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20return(false);"%20href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663087&version=HealthProfessional&language=English"%20class="Summary-LOERef">Level%20of%20evidence:%20III</a>)  New-onset hypophosphatemia  and hypomagnesemia may occur; pre-existing abnormalities in the same electrolytes may be  exacerbated by treatment.  Serum calcium may fall below the normal range, and  hypocalcemia (typically asymptomatic) may result.  Renal failure has only been  reported after rapid etidronate and clodronate injection, but rapid  administration should be avoided with all bisphosphonates.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.23">23</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.23">23</a>)[<a>click="javascript:popWindow('defbyid','CDR0000663087&version=HealthProfessional&language=English');                         return(false);" href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663087&version=HealthProfessional&language=English" class="Summary-LOERef">Level of evidence: III</a>](<a>click="javascript:popWindow('defbyid','CDR0000663087&version=HealthProfessional&language=English');%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20return(false);"%20href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663087&version=HealthProfessional&language=English"%20class="Summary-LOERef">Level%20of%20evidence:%20III</a>)  Intravenous pamidronate administration has been associated with acute-phase responses, including transiently decreased peripheral lymphocyte counts.  Local reactions (thrombophlebitis, erythema, and pain) at the infusion site have been reported.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.21">21</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.21">21</a>)</p>

<a></a>

<p>The use of subcutaneous (SC) administration of clodronate has been explored.  Initial experience suggested that  clodronate was well tolerated subcutaneously; however, aminobisphosphonates such as pamidronate  resulted in local irritation.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.24">24</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.24">24</a>)   In a subsequent study, 37 inpatients with terminal cancer received 45 clodronate infusions.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.25">25</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.25">25</a>)[<a>click="javascript:popWindow('defbyid','CDR0000663072&version=HealthProfessional&language=English');                         return(false);" href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663072&version=HealthProfessional&language=English" class="Summary-LOERef">Level of evidence: II</a>](<a>click="javascript:popWindow('defbyid','CDR0000663072&version=HealthProfessional&language=English');%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20return(false);"%20href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663072&version=HealthProfessional&language=English"%20class="Summary-LOERef">Level%20of%20evidence:%20II</a>)  Clodronate, 1,500 mg in 1 L of normal saline, was administered via a 23-gauge, ¾-inch butterfly  needle into the SC space.  All the infusions were completed, and none required discontinuation due to discomfort.  The authors concluded that their  results suggested that SC clodronate is an effective treatment for hypercalcemia of malignancy and is associated with minimal toxicity.   This technique has advantages in the care of terminally ill patients at home  and may avoid the need for hospital admission and/or IV administration.  In addition, SC administration in the hospital setting has advantages for patients for whom an IV site may be problematic.</p>

<a></a>

<p>Calcitonin and plicamycin have a more rapid hypocalcemic  effect than bisphosphonates; however, pamidronate has several advantages over nonbisphosphonate therapies.  In comparison with plicamycin, response  rates are greater among patients treated with pamidronate.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.26">26</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.26">26</a>)[<a>click="javascript:popWindow('defbyid','CDR0000663069&version=HealthProfessional&language=English');                         return(false);" href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663069&version=HealthProfessional&language=English" class="Summary-LOERef">Level of evidence: I</a>](<a>click="javascript:popWindow('defbyid','CDR0000663069&version=HealthProfessional&language=English');%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20return(false);"%20href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663069&version=HealthProfessional&language=English"%20class="Summary-LOERef">Level%20of%20evidence:%20I</a>)  Pamidronate more frequently reduces serum calcium concentrations to normocalcemic ranges  than either calcitonin or plicamycin.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.26">26</a>,<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.27">27</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.26">26</a>,<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.27">27</a>)[<a>click="javascript:popWindow('defbyid','CDR0000663069&version=HealthProfessional&language=English');                         return(false);" href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663069&version=HealthProfessional&language=English" class="Summary-LOERef">Level of evidence: I</a>](<a>click="javascript:popWindow('defbyid','CDR0000663069&version=HealthProfessional&language=English');%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20return(false);"%20href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663069&version=HealthProfessional&language=English"%20class="Summary-LOERef">Level%20of%20evidence:%20I</a>)  In addition, pamidronate’s hypocalcemic effect is dose related and sustained after repeated administration, and it generally persists longer than the effects  produced by either calcitonin or plicamycin therapies.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.19">19</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.19">19</a>)[<a>click="javascript:popWindow('defbyid','CDR0000663069&version=HealthProfessional&language=English');                         return(false);" href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663069&version=HealthProfessional&language=English" class="Summary-LOERef">Level of evidence: I</a>](<a>click="javascript:popWindow('defbyid','CDR0000663069&version=HealthProfessional&language=English');%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20return(false);"%20href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663069&version=HealthProfessional&language=English"%20class="Summary-LOERef">Level%20of%20evidence:%20I</a>)  Pamidronate lacks the renal, hepatic, and platelet toxic effects associated with plicamycin.</p>

<a></a>   <a></a>   <span class="Summary-SummarySection-Title-Level3">Calcitonin </span>   <a></a>

<p>Calcitonin is a peptide hormone secreted by specialized  cells in the thyroid and parathyroid.  Its synthesis and secretion normally increase in  response to high concentrations of serum-ionized calcium.  Calcitonin opposes  physiologic effects of parathyroid hormone on bone and renal tubular calcium  resorption; however, it is not known whether calcitonin has a significant role in  calcium homeostasis.  Nevertheless, calcitonin rapidly inhibits calcium and  phosphorous resorption from bone and decreases renal calcium reabsorption.   Calcitonin derived from salmon is much more potent and is longer acting than the human hormone.  The initial dose schedule is 4 IU/kg of body  weight per SC dose or intramuscular (IM) dose every 12 hours.  Dose and schedule may be escalated after 1 or 2 days to 8 IU/kg every 12 hours,  and finally to 8 IU/kg every 6 hours if the response to lower doses is unsatisfactory.  Unfortunately, tachyphylaxis commonly occurs.  With  repeated use, calcitonin’s beneficial hypocalcemic effect wanes, even at the  upper recommended limits of dose and schedule, so that its calcium-lowering  effect lasts for only a few days.  In patients who are responsive to  calcitonin, its combination with bisphosphonates may hasten the onset and duration of a hypocalcemic response caused by calcitonin’s rapid (within 2–4 hours)  onset of action.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.28">28</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.28">28</a>)[<a>click="javascript:popWindow('defbyid','CDR0000663072&version=HealthProfessional&language=English');                         return(false);" href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663072&version=HealthProfessional&language=English" class="Summary-LOERef">Level of evidence: II</a>](<a>click="javascript:popWindow('defbyid','CDR0000663072&version=HealthProfessional&language=English');%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20return(false);"%20href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663072&version=HealthProfessional&language=English"%20class="Summary-LOERef">Level%20of%20evidence:%20II</a>);[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.29">29</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.29">29</a>)[<a>click="javascript:popWindow('defbyid','CDR0000663089&version=HealthProfessional&language=English');                         return(false);" href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663089&version=HealthProfessional&language=English" class="Summary-LOERef">Level of evidence: IV</a>](<a>click="javascript:popWindow('defbyid','CDR0000663089&version=HealthProfessional&language=English');%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20return(false);"%20href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663089&version=HealthProfessional&language=English"%20class="Summary-LOERef">Level%20of%20evidence:%20IV</a>)</p>

<a></a>

<p>Calcitonin is usually well tolerated; adverse effects  include mild nausea, transient cramping abdominal pain, and cutaneous flushing.  Calcitonin  is most useful within the first 24 to 36 hours of treatment of severe  hypercalcemia and should be used in conjunction with more potent but slower-acting agents.</p>

<a></a>   <a></a>   <span class="Summary-SummarySection-Title-Level3">Plicamycin</span>   <a></a>

<p>Plicamycin (also referred to as mithramycin) is an  inhibitor of osteoclast RNA synthesis.  It has been shown to inhibit bone resorption <i>in vitro</i>  and is clinically effective in the presence or absence of bone metastases.   Onset of response occurs within 12 hours of a single IV dose of 25 to 30 ?g/kg of body weight given as a short infusion for 30 minutes or longer.   Maximum response, however, does not occur until approximately 48 hours after administration and may persist for 3 to 7 days or more after  administration.  Repeated doses may be given to maintain plicamycin’s hypocalcemic effect  but should not be given more frequently than every 48 hours to determine the maximum calcium-lowering effect produced by previous doses.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.30">30</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.30">30</a>)   Multiple doses may control hypercalcemia for several weeks, but rebound  hypercalcemia usually occurs without definitive treatment against the underlying malignancy.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.31">31</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.31">31</a>)   Although single-dose treatment of hypercalcemia is generally well tolerated with few adverse effects,[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.32">32</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.32">32</a>)[<a>click="javascript:popWindow('defbyid','CDR0000663072&version=HealthProfessional&language=English');                         return(false);" href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663072&version=HealthProfessional&language=English" class="Summary-LOERef">Level of evidence: II</a>](<a>click="javascript:popWindow('defbyid','CDR0000663072&version=HealthProfessional&language=English');%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20return(false);"%20href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663072&version=HealthProfessional&language=English"%20class="Summary-LOERef">Level%20of%20evidence:%20II</a>) dysfibrinogenemia [<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.33">33</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.33">33</a>)[<a>click="javascript:popWindow('defbyid','CDR0000663087&version=HealthProfessional&language=English');                         return(false);" href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663087&version=HealthProfessional&language=English" class="Summary-LOERef">Level of evidence: III</a>](<a>click="javascript:popWindow('defbyid','CDR0000663087&version=HealthProfessional&language=English');%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20return(false);"%20href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663087&version=HealthProfessional&language=English"%20class="Summary-LOERef">Level%20of%20evidence:%20III</a>) and nephrotoxicity [<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.34">34</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.34">34</a>)  have been reported after single doses (20–25 ?g/kg).  Rapid IV administration is associated with nausea and vomiting.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.31">31</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.31">31</a>)   High and repeated doses predispose the patient to thrombocytopenia, a  qualitative platelet dysfunction that may be associated with a bleeding diathesis, transient increases in hepatic transaminases, nephrotoxicity (decreased creatinine clearance, increased serum creatinine and blood urea  nitrogen, potassium wasting, and proteinuria), hypophosphatemia, a flulike syndrome, dermatologic reactions, and stomatitis.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.31">31</a>,<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.34">34</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.31">31</a>,<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.34">34</a>);[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.35">35</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.35">35</a>)[<a>click="javascript:popWindow('defbyid','CDR0000663072&version=HealthProfessional&language=English');                         return(false);" href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663072&version=HealthProfessional&language=English" class="Summary-LOERef">Level of evidence: II</a>](<a>click="javascript:popWindow('defbyid','CDR0000663072&version=HealthProfessional&language=English');%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20return(false);"%20href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663072&version=HealthProfessional&language=English"%20class="Summary-LOERef">Level%20of%20evidence:%20II</a>);[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.36">36</a>-<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.39">39</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.36">36</a>-<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.39">39</a>)[<a>click="javascript:popWindow('defbyid','CDR0000663087&version=HealthProfessional&language=English');                         return(false);" href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663087&version=HealthProfessional&language=English" class="Summary-LOERef">Level of evidence: III</a>](<a>click="javascript:popWindow('defbyid','CDR0000663087&version=HealthProfessional&language=English');%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20return(false);"%20href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663087&version=HealthProfessional&language=English"%20class="Summary-LOERef">Level%20of%20evidence:%20III</a>)</p>

<a></a>   <a></a>   <span class="Summary-SummarySection-Title-Level3">Gallium nitrate</span>   <a></a>

<p>Gallium nitrate was developed as an antineoplastic agent  that was coincidentally found to produce a hypocalcemic effect.  Gallium nitrate interferes with an adenosine triphosphatase–dependent proton pump in the membrane of osteoclasts.  This impairs osteoclast acidification and the dissolution of the underlying bone matrix.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.1">1</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.1">1</a>)   Gallium nitrate has been shown to be superior to etidronate in the percentage of patients who achieve normocalcemia and in the duration of normocalcemia.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.40">40</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.40">40</a>)[<a>click="javascript:popWindow('defbyid','CDR0000663069&version=HealthProfessional&language=English');                         return(false);" href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663069&version=HealthProfessional&language=English" class="Summary-LOERef">Level of evidence: I</a>](<a>click="javascript:popWindow('defbyid','CDR0000663069&version=HealthProfessional&language=English');%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20return(false);"%20href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663069&version=HealthProfessional&language=English"%20class="Summary-LOERef">Level%20of%20evidence:%20I</a>)  Drawbacks to its use include a continuous 5-day IV infusion schedule (200 mg/m<sup>2</sup> of body surface area per day) [<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.6">6</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.6">6</a>)  and the potential for nephrotoxicity, particularly when it is used concurrently with other potentially nephrotoxic drugs  (e.g., aminoglycosides and amphotericin B).[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.1">1</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.1">1</a>)</p>

<a></a>

<p>Gallium nitrate has also been given by daily SC  injection to prevent bone resorption and maintain bone mass in patients with multiple  myeloma.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.41">41</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.41">41</a>)[<a>click="javascript:popWindow('defbyid','CDR0000663069&version=HealthProfessional&language=English');                         return(false);" href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663069&version=HealthProfessional&language=English" class="Summary-LOERef">Level of evidence: I</a>](<a>click="javascript:popWindow('defbyid','CDR0000663069&version=HealthProfessional&language=English');%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20return(false);"%20href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663069&version=HealthProfessional&language=English"%20class="Summary-LOERef">Level%20of%20evidence:%20I</a>)</p>

<a></a>   <a></a>   <a></a>   <span class="Summary-SummarySection-Title-Level2">Other Therapeutics  for Hypercalcemia</span><br /><br /><a></a>   <span class="Summary-SummarySection-Title-Level3">Glucocorticoids</span>   <a></a>

<p>Glucocorticoids have efficacy as hypocalcemic agents  primarily in steroid-responsive tumors (e.g., lymphomas and myeloma) and in patients  whose hypercalcemia is associated with increased vitamin D synthesis or intake (sarcoidosis and hypervitaminosis D).[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.42">42</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.42">42</a>)[<a>click="javascript:popWindow('defbyid','CDR0000663087&version=HealthProfessional&language=English');                         return(false);" href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663087&version=HealthProfessional&language=English" class="Summary-LOERef">Level of evidence: III</a>](<a>click="javascript:popWindow('defbyid','CDR0000663087&version=HealthProfessional&language=English');%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20return(false);"%20href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663087&version=HealthProfessional&language=English"%20class="Summary-LOERef">Level%20of%20evidence:%20III</a>);[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.43">43</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.43">43</a>)[<a>click="javascript:popWindow('defbyid','CDR0000663072&version=HealthProfessional&language=English');                         return(false);" href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663072&version=HealthProfessional&language=English" class="Summary-LOERef">Level of evidence: II</a>](<a>click="javascript:popWindow('defbyid','CDR0000663072&version=HealthProfessional&language=English');%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20return(false);"%20href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663072&version=HealthProfessional&language=English"%20class="Summary-LOERef">Level%20of%20evidence:%20II</a>)  Glucocorticoids increase  urinary calcium excretion and inhibit vitamin D–mediated gastrointestinal  calcium absorption.  Response, however, is typically slow; 1 to 2 weeks may  elapse before serum calcium concentrations decrease.  Oral hydrocortisone  (100–300 mg) or its glucocorticoid equivalent may be given daily; however,  complications of long-term steroid use limit its usefulness even in responsive patients.</p>

<a></a>   <a></a>   <span class="Summary-SummarySection-Title-Level3">Phosphate </span>   <a></a>

<p>Phosphate offers a minimally effective chronic oral  treatment for mild to moderate hypercalcemia.  It is most useful after successful initial  reduction of serum calcium with other agents and should probably be reserved for  patients who are both hypercalcemic and hypophosphatemic.  The usual treatment is  250 to 375 mg per dose given 4 times daily (1–1.5 g of elemental phosphorus per  day) to minimize the potential for developing hyperphosphatemia.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.44">44</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.44">44</a>)   Supranormal phosphate administration results in decreased renal calcium clearance  and presumably decreases serum calcium concentrations by precipitating  calcium into bone and soft tissues.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.45">45</a>,<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.46">46</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.45">45</a>,<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.46">46</a>)[<a>click="javascript:popWindow('defbyid','CDR0000663072&version=HealthProfessional&language=English');                         return(false);" href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663072&version=HealthProfessional&language=English" class="Summary-LOERef">Level of evidence: II</a>](<a>click="javascript:popWindow('defbyid','CDR0000663072&version=HealthProfessional&language=English');%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20return(false);"%20href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663072&version=HealthProfessional&language=English"%20class="Summary-LOERef">Level%20of%20evidence:%20II</a>)  Extraskeletal precipitation  of calcium in vital organs may have adverse consequences and is especially significant after intravenous administration.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.6">6</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.6">6</a>);[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.47">47</a>,<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.48">48</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.47">47</a>,<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.48">48</a>)[<a>click="javascript:popWindow('defbyid','CDR0000663087&version=HealthProfessional&language=English');                         return(false);" href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663087&version=HealthProfessional&language=English" class="Summary-LOERef">Level of evidence: III</a>](<a>click="javascript:popWindow('defbyid','CDR0000663087&version=HealthProfessional&language=English');%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20return(false);"%20href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663087&version=HealthProfessional&language=English"%20class="Summary-LOERef">Level%20of%20evidence:%20III</a>)  IV administration of  phosphate produces a rapid decline in serum calcium concentrations but is rarely  used because there are safer and more effective antiresorptive agents for life-threatening hypercalcemia (calcitonin and plicamycin).   Hypotension, oliguria, left ventricular failure, and sudden death can occur as a  result of rapid IV administration.  Contraindications for phosphate include normophosphatemia, hyperphosphatemia, and renal insufficiency.  Oral  phosphate should be given at the lowest dose possible to maintain serum  phosphorous concentrations lower than 4 mg/dL 1 to 2 hours after administration.</p>

<a></a>

<p>The use of phosphates is limited by individual patient  tolerance and toxicity; 25% to 50% of patients cannot tolerate oral phosphates.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.8">8</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.8">8</a>)   Oral  phosphate–induced diarrhea may be initially advantageous in patients who  have experienced constipation secondary to hypercalcemia; it is the  predominant and dose-limiting adverse effect for oral therapy and frequently prevents  dosage escalation of more than 2 g of neutral phosphate per day.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.6">6</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.6">6</a>)</p>

<a></a>   <a></a>   <span class="Summary-SummarySection-Title-Level3">Dialysis</span>   <a></a>

<p>Dialysis is an option for hypercalcemia that is  complicated by renal failure.  Peritoneal dialysis with calcium-free dialysate fluid can remove 200 to  2,000 mg of calcium in 24 to 48 hours and decrease the serum calcium  concentration by 3 to 12 mg/dL (1.5–6 mEq/L or 0.7–3 mmol/L).  Ultrafiltrable calcium  clearance may exceed that of urea with calcium-free dialysate exchanges of 2 L  each every 30 minutes.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.49">49</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.49">49</a>)   Hemodialysis is equally effective.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.50">50</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.50">50</a>)[<a>click="javascript:popWindow('defbyid','CDR0000663087&version=HealthProfessional&language=English');                         return(false);" href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663087&version=HealthProfessional&language=English" class="Summary-LOERef">Level of evidence: III</a>](<a>click="javascript:popWindow('defbyid','CDR0000663087&version=HealthProfessional&language=English');%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20return(false);"%20href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663087&version=HealthProfessional&language=English"%20class="Summary-LOERef">Level%20of%20evidence:%20III</a>);[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.51">51</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.51">51</a>)[<a>click="javascript:popWindow('defbyid','CDR0000663089&version=HealthProfessional&language=English');                         return(false);" href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663089&version=HealthProfessional&language=English" class="Summary-LOERef">Level of evidence: IV</a>](<a>click="javascript:popWindow('defbyid','CDR0000663089&version=HealthProfessional&language=English');%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20return(false);"%20href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663089&version=HealthProfessional&language=English"%20class="Summary-LOERef">Level%20of%20evidence:%20IV</a>)  Because large quantities of phosphate are lost during dialysis and phosphate loss  aggravates hypercalcemia, serum inorganic phosphate should be measured after each  dialysis session, and phosphate should be added to the dialysate during the next  fluid exchange or to the patient’s diet.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.52">52</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.52">52</a>)[<a>click="javascript:popWindow('defbyid','CDR0000663087&version=HealthProfessional&language=English');                         return(false);" href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663087&version=HealthProfessional&language=English" class="Summary-LOERef">Level of evidence: III</a>](<a>click="javascript:popWindow('defbyid','CDR0000663087&version=HealthProfessional&language=English');%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20return(false);"%20href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663087&version=HealthProfessional&language=English"%20class="Summary-LOERef">Level%20of%20evidence:%20III</a>)  It is recommended,  however, that phosphate replacement should be limited to restoring serum inorganic  phosphate concentrations to normal rather than supranormal.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.44">44</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.44">44</a>)</p>

<a></a>   <a></a>   <span class="Summary-SummarySection-Title-Level3">Prostaglandin  synthesis Inhibitors </span>   <a></a>

<p>Prostaglandin synthesis inhibitors such as the  nonsteroidal anti-inflammatory drugs may have some efficacy in the management of cancer-induced  hypercalcemia.  The E-series prostaglandins mediate bone resorption.  Despite  experimental evidence, however, aspirin and other nonsteroidal drugs have  demonstrated only modest clinical response rates in controlling hypercalcemia.  For  patients who are unresponsive to or unable to tolerate other agents, aspirin may be  given to produce a serum salicylate concentration equal to 20 to 30 mg/dL, or 25  mg indomethacin may be given orally every 6 hours.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.53">53</a>-<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.55">55</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.53">53</a>-<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.55">55</a>)[<a>click="javascript:popWindow('defbyid','CDR0000663072&version=HealthProfessional&language=English');                         return(false);" href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663072&version=HealthProfessional&language=English" class="Summary-LOERef">Level of evidence: II</a>](<a>click="javascript:popWindow('defbyid','CDR0000663072&version=HealthProfessional&language=English');%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20return(false);"%20href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663072&version=HealthProfessional&language=English"%20class="Summary-LOERef">Level%20of%20evidence:%20II</a>);[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.56">56</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.56">56</a>)[<a>click="javascript:popWindow('defbyid','CDR0000663087&version=HealthProfessional&language=English');                         return(false);" href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663087&version=HealthProfessional&language=English" class="Summary-LOERef">Level of evidence: III</a>](<a>click="javascript:popWindow('defbyid','CDR0000663087&version=HealthProfessional&language=English');%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20%20return(false);"%20href="http://www.cancer.gov/Common/PopUps/popDefinition.aspx?id=663087&version=HealthProfessional&language=English"%20class="Summary-LOERef">Level%20of%20evidence:%20III</a>)</p>

<a></a>   <a></a>   <span class="Summary-SummarySection-Title-Level3">Cisplatin</span>   <a></a>

<p>Serum calcium was normalized for a median of 34 days  (range, 4–115) in 9 of 13 patients with various solid tumors given IV cisplatin at 100 mg/m<sup>2</sup> of body surface area  over 24 hours.  Patients were re-treated as frequently as every 7 days if necessary to maintain serum calcium concentrations lower than 11.5 mg/dL (<5.75 mEq/L or 2.87 mmol/L).   Four of seven  patients responded to repeated treatment.  Responders achieved a  statistically significant difference in serum calcium levels from baseline on the  tenth day after treatment, which continued thereafter.  Serial tumor measurements revealed that the hypocalcemic response did not correlate with tumor  shrinkage; there was no detectable antitumor response in any measurable or  evaluable disease.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.57">57</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.57">57</a>)</p>

<a></a>

<p>Future pharmacologic management is likely to combine  osteoclastic inhibitors with cytotoxic or endocrine therapy.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.9">9</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.9">9</a>)</p>

<a></a>   <a></a>   <a></a>   <span class="Summary-SummarySection-Title-Level2">Patient and Family  Education</span>   <a></a>

<p>Hypercalcemia compromises the patient’s quality of life  and can be life-threatening if not promptly recognized and treated.  Individuals at  risk and their caregivers should be made aware that hypercalcemia is a  possible complication.  Patients and their significant others should be advised  about the types of symptoms that may occur with hypercalcemia, preventive  measures, exacerbating factors, and when to seek medical assistance.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.58">58</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.58">58</a>)  They should be taught measures to diminish the symptoms of hypercalcemia such as  maintaining mobility and ensuring adequate hydration.</p>

<a></a>   <a></a>   <span class="Summary-SummarySection-Title-Level2">Supportive Care</span>   <a></a>

<p>Despite encouraging developments in pharmacologic  management, the prognostic implications related to hypercalcemia remain relatively grim.  Only  patients for whom effective anticancer therapy is possible can be expected to  experience a longer survival.</p>

<a></a>

<p>The adverse effects of therapy need to be prevented or  recognized and managed.  Fluid overload and electrolyte imbalance can occur during initial  therapy.  Serum sodium, potassium, calcium, phosphate, and magnesium  concentrations may be markedly decreased.  Electrolyte levels should be monitored at least  daily, and clinical signs and symptoms should be assessed at least every 4  hours when hydration or specific hypocalcemic drug treatments are being  implemented.</p>

<a></a>

<p>The management of symptoms of hypercalcemia is crucial.   Preventing accidental or self-inflicted injury as a consequence of the patient’s altered  mental status is a priority during acute management.  Until serum calcium  decreases, additional pharmacologic interventions may be necessary to control  nausea, vomiting, and constipation.</p>

<a></a>

<p>Any acute severe exacerbation or development of new  bone pain should be evaluated for the presence of a pathological fracture.  Many health care facilities institute fracture precautions for patients with metastatic  disease to the bone.  These precautions include gentle handling when moving or transferring patients and fall-prevention strategies.  Maximum mobility  and weight-bearing exercises are desirable.</p>

<a></a>

<p>Supportive care in terminal stages typically consists  of comfort measures for patients and their caregivers.  Changes in mentation and behavior may be especially distressing to family members.</p>

<a></a>   <a></a>   <span class="Summary-SummarySection-Title-Level2">Psychosocial  Management</span>   <a></a>

<p>Supportive management of delirium, agitation, or  changes in mental status is implemented in patients with hypercalcemia.  Primary treatment of   hypercalcemia and/or its underlying etiology eventually leads to the    resolution of changes in mental status in most of these patients.  Some  patients present with clinically significant and distressing changes in mental  status, agitation, or delirium that warrants management or control. (Refer to  the PDQ summary on <a class="SummaryRef" href="http://www.cancer.gov/cancertopics/pdq/supportivecare/delirium/HealthProfessional">Cognitive  Disorders and Delirium</a> for more information.)  Clinical experience  supports the use of neuroleptic medications such as haloperidol (0.5–5.0 mg IV or by  mouth  2–4 times a day) alone or in combination with benzodiazepines (e.g., 0.5–2.0 mg of lorazepam IV or by  mouth 2–4 times a day) for the control of agitation and confusion.  This enhances patient and family comfort and allows for  easier institution of primary therapies.  The use of benzodiazepines in these situations should be reserved for instances in which sedation (and not improvement in mental status) is the primary goal of the intervention.</p>

<a></a>

<p>The relationship between mental status and serum  calcium levels is variable.  Some patients will not manifest improvement in mental status until days  to a week or more after serum calcium levels are in the normal range; others  will display improvement before laboratory values catch up.</p>

<a></a>

<p>Many times, lethargy is a presenting symptom of  hypercalcemia.  Lethargic    patients are often mistakenly believed by family (and sometimes by  staff) to be depressed before the actual etiology of the mental-status changes  becomes known.  The differential diagnosis is generally straightforward in that  many of these patients will lack the cognitive or ideational symptoms of a mood disorder (hopelessness, helplessness, anhedonia, guilt, worthlessness,  or thoughts of suicide) and instead will appear mainly lethargic and  apathetic; formal testing of mental status is likely to reveal cognitive  deficits.  This is an important distinction to be made, as the introduction of  antidepressant drugs during an organic confusional episode can worsen confusion.</p>

<a></a>   <span class="Summary-SummarySection-Title-Level3">Management of  hypercalcemia </span>   <a></a>

<ol class="Protocol-OL"><li class="Protocol-OL-Arabic">Correct dehydration due to  calciuresis and vomiting with IV    hydration using isotonic saline.</li>

<li class="Protocol-OL-Arabic">Prevent or manage fluid overload with  a diuretic such as furosemide, 20 mg to 40 mg every 12 hours.</li>

<li class="Protocol-OL-Arabic">Treat hypercalcemia with one of the  following agents:<a></a><a></a>

<ul class="Protocol-UL"><li class="Protocol-IL-Bullet">pamidronate,  60 to 90 mg IV over 2 to 24 hours.</li>

<li class="Protocol-IL-Bullet">calcitonin,  4 IU/kg SC or IM every 12 hours.</li>

<li class="Protocol-IL-Bullet">plicamycin,  25 to 30 ?g/kg IV over 30 minutes.</li>

<li class="Protocol-IL-Bullet">gallium  nitrate, 200 mg/m<sup>2</sup> per day IV over 24 hours for 5 consecutive days.</li>

</ul><a></a></li>

<li class="Protocol-OL-Arabic">Provide patient and family education:<a></a><a></a>

<ul class="Protocol-UL"><li class="Protocol-IL-Bullet">Signs and symptoms of  hypercalcemia to report to the health care provider:<a></a><a></a>

<ul class="Protocol-UL"><li class="Protocol-IL-Dash">Lethargy.</li>

<li class="Protocol-IL-Dash">Fatigue.</li>

<li class="Protocol-IL-Dash">Confusion.</li>

<li class="Protocol-IL-Dash">Loss of appetite.</li>

<li class="Protocol-IL-Dash">Nausea/vomiting.</li>

<li class="Protocol-IL-Dash">Constipation.</li>

<li class="Protocol-IL-Dash">Excessive thirst.</li>

</ul><a></a></li>

<li class="Protocol-IL-Bullet">Preventive measures:<a></a><a></a>

<ul class="Protocol-UL"><li class="Protocol-IL-Dash">Maintain mobility.</li>

<li class="Protocol-IL-Dash">Ensure adequate hydration.</li>

</ul><a></a></li>

</ul><a></a></li>

<li class="Protocol-OL-Arabic">Provide supportive care:<a></a><a></a>

<ul class="Protocol-UL"><li class="Protocol-IL-Bullet">Protect from injury.</li>

<li class="Protocol-IL-Bullet">Prevent fractures.</li>

<li class="Protocol-IL-Bullet">Manage related symptoms (e.g.,  nausea, vomiting, and constipation).</li>

</ul><a></a></li>

<li class="Protocol-OL-Arabic">Manage mental-status changes:<a></a><a></a>

<ul class="Protocol-UL"><li class="Protocol-IL-Bullet">Haloperidol, 0.5 to 5  mg IV or by mouth 2 to 4 times a day for agitation or confusion.</li>

<li class="Protocol-IL-Bullet">Benzodiazepines such as lorazepam,  0.5 to 2 mg every 4 to 6 hours as needed for sedation.</li>

</ul><a></a></li>

</ol><a></a>   <a></a>   <a></a>   <span class="Summary-SummarySection-Title-Level2">Prognosis</span>   <a></a>

<p>Hypercalcemia generally develops as a late complication  of malignancy; its appearance has grave prognostic significance.  It remains unclear,  however, whether death is associated with hypercalcemic crisis (uncontrolled or recurrent progressive hypercalcemia) or with advanced disease.   Currently available hypocalcemic agents have little effect in decreasing the  mortality rate among patients with hypercalcemia of malignancy.  Although there is  some disagreement among investigators who have evaluated survival among  patients with cancer-related hypercalcemia,[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.59">59</a>-<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.62">62</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.59">59</a>-<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.62">62</a>)  it has been observed that 50% of patients with hypercalcemia die within 1 month and 75% within 3 months  after starting hypocalcemic treatment.  In the same study, patients with hypercalcemia who responded to specific antineoplastic treatment were  found to have a slightly greater survival advantage over nonresponders.  Other prognostic variables shown to correlate with longer survival included  serum albumin concentration (direct correlation), serum calcium concentrations after treatment (inverse correlation), and age (inverse correlation).[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.5">5</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.5">5</a>)   In contrast with their modest effect on survival, marked but differential response rates were observed after hypocalcemic treatments  as a factor of symptom type.  The most substantial improvements occurred in  renal- and central nervous system–related symptoms (nausea, vomiting,  and constipation).  Symptoms of anorexia, malaise, and fatigue improved, but  less completely.[<a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.5">5</a>](<a%20href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#Reference6.5">5</a>)</p>

<a></a>   <a></a>

<p><span class="Summary-ReferenceSection"> 						References 					</span></p>

<ol><li><a></a>Warrell RP Jr: Metabolic emergencies.  In: DeVita VT Jr, Hellman S, Rosenberg SA, eds.: Cancer: Principles and  Practice of Oncology. 5th ed. Philadelphia, Pa: Lippincott-Raven  Publishers, 1997, pp 2486-93.  			<br />

</li>

<li><a></a>Bilezikian JP: Management of acute  hypercalcemia. N Engl J Med 326 (18): 1196-203, 1992.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1532633&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Theriault RL: Hypercalcemia of  malignancy: pathophysiology and implications for treatment. Oncology  (Huntingt) 7 (1): 47-50; discussion 52-5, 1993.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8420542&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Mundy GR: Pathophysiology of  cancer-associated hypercalcemia. Semin Oncol 17 (2 Suppl 5): 10-5,  1990.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2185548&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Ralston SH, Gallacher SJ, Patel U, et  al.: Cancer-associated hypercalcemia: morbidity and mortality. Clinical  experience in 126 treated patients. Ann Intern Med 112 (7): 499-504,  1990.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2138442&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Ritch PS: Treatment of cancer-related  hypercalcemia. Semin Oncol 17 (2 Suppl 5): 26-33, 1990.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2185550&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Suki WN, Yium JJ, Von Minden M, et  al.: Acute treatment of hypercalcemia with furosemide. N Engl J Med 283  (16): 836-40, 1970.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=5458033&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Ignoffo RJ, Tseng A: Focus on  pamidronate: a biphosphonate compound for the treatment of hypercalcemia  of malignancy. Hosp Formul  26 (10): 774-86, 1991.  			<br />

</li>

<li><a></a>Warrell RP Jr: Etiology and current  management of cancer-related hypercalcemia. Oncology (Huntingt) 6 (10):  37-43; discussion 43, 47-50, 1992.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1390013&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Coleman RE: Bisphosphonate treatment  of bone metastases and hypercalcemia of malignancy. Oncology (Huntingt)  5 (8): 55-60; discussion 60-2, 65, 1991.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1834153&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>McCloskey EV, Yates AJ, Beneton MN,  et al.: Comparative effects of intravenous diphosphonates on calcium and  skeletal metabolism in man. Bone 8 (Suppl 1): S35-41, 1987.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2825741&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Mautalen C, Gonzalez D, Blumenfeld  EL, et al.: Spontaneous fractures of uninvolved bones in patients with  Paget's disease during unduly prolonged treatment with disodium  etidronate (EHDP). Clin Orthop  (207): 150-5, 1986.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3087670&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Fleisch H: Bisphosphonates.  Pharmacology and use in the treatment of tumour-induced hypercalcaemic  and metastatic bone disease. Drugs 42 (6): 919-44, 1991.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1724640&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Fenton AJ, Gutteridge DH, Kent GN,  et al.: Intravenous aminobisphosphonate in Paget's disease: clinical,  biochemical, histomorphometric and radiological responses. Clin  Endocrinol (Oxf) 34 (3): 197-204, 1991.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2036728&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Adamson BB, Gallacher SJ, Byars J,  et al.: Mineralisation defects with pamidronate therapy for Paget's  disease. Lancet 342 (8885): 1459-60, 1993.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7902484&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Boyce BF, Adamson BB, Gallacher SJ,  et al.: Mineralisation defects after pamidronate for Paget's disease.  Lancet 343 (8907): 1231-2, 1994.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7909901&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Gucalp R, Ritch P, Wiernik PH, et  al.: Comparative study of pamidronate disodium and etidronate disodium  in the treatment of cancer-related hypercalcemia. J Clin Oncol 10 (1):  134-42, 1992.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1727915&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Novartis Pharmaceuticals  Corporation.: Aredia: package insert. May 1998.  			<br />

</li>

<li><a></a>Elomaa I, Blomqvist C, Porkka L, et  al.: Diphosphonates for osteolytic metastases. Lancet 1 (8438): 1155-6,  1985.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2860356&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Kerdudo C, Aerts I, Fattet S, et  al.: Hypercalcemia and childhood cancer: a 7-year experience. J Pediatr  Hematol Oncol 27 (1): 23-7, 2005.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15654274&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Nussbaum SR, Younger J, Vandepol CJ,  et al.: Single-dose intravenous therapy with pamidronate for the  treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and  90-mg dosages. Am J Med 95 (3): 297-304, 1993.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8368227&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Burckhardt P, Thiébaud D, Perey L,  et al.: Treatment of tumor-induced osteolysis by APD. Recent Results  Cancer Res 116: 54-66, 1989.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2762665&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Bounameaux HM, Schifferli J, Montani  JP, et al.: Renal failure associated with intravenous diphosphonates.  Lancet 1 (8322): 471, 1983.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6131186&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Walker P, Watanabe S, Lawlor P, et  al.: Subcutaneous clodronate. Lancet 348 (9023): 345-6, 1996.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8709722&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Walker P, Watanabe S, Lawlor P, et  al.: Subcutaneous clodronate: a study evaluating efficacy in  hypercalcemia of malignancy and local toxicity. Ann Oncol 8 (9): 915-6,  1997.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9358945&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Ostenstad B, Andersen OK: Disodium  pamidronate versus mithramycin in the management of tumour-associated  hypercalcemia. Acta Oncol 31 (8): 861-4, 1992.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1290634&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Ralston SH, Gardner MD, Dryburgh FJ,  et al.: Comparison of aminohydroxypropylidene diphosphonate,  mithramycin, and corticosteroids/calcitonin in treatment of  cancer-associated hypercalcaemia. Lancet 2 (8461): 907-10, 1985.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2865417&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Thiébaud D, Jacquet AF, Burckhardt  P: Fast and effective treatment of malignant hypercalcemia. Combination  of suppositories of calcitonin and a single infusion of 3-amino  1-hydroxypropylidene-1-bisphosphonate. Arch Intern Med 150 (10): 2125-8,  1990.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2222097&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Ralston SH, Gallacher SJ, Dryburgh  FJ, et al.: Treatment of severe hypercalcaemia with mithramycin and  aminohydroxypropylidene bisphosphonate. Lancet 2 (8605): 277, 1988.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2899259&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Parsons V, Baum M, Self M: Effect of  mithramycin on calcium and hydroxyproline metabolism in patients with  malignant disease. Br Med J 1 (538): 474-7, 1967.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6017527&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Kennedy BJ: Metabolic and toxic  effects of mithramycin during tumor therapy. Am J Med 49 (4): 494-503,  1970.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4320120&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Perlia CP, Gubisch NJ, Wolter J, et  al.: Mithramycin treatment of hypercalcemia. Cancer 25 (2): 389-94,  1970.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=5413510&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Ashby MA, Lazarchick J: Acquired  dysfibrinogenemia secondary to mithramycin toxicity. Am J Med Sci 292  (1): 53-5, 1986.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2940861&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Benedetti RG, Heilman KJ 3rd, Gabow  PA: Nephrotoxicity following single dose mithramycin therapy. Am J  Nephrol 3 (5): 277-8, 1983 Sep-Oct.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6227249&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Fillastre JP, Maitrot J, Canonne MA,  et al.: Renal function and alterations in plasma electrolyte levels in  normocalcaemic and hypercalaemic patients with malignant diseases, given  an intravenous infusion of mithramycin. Chemotherapy 20 (5): 280-95,  1974.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4278249&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Purpora D, Ahern MJ, Silverman N:  Toxic epidermal necrolysis after mithramycin. N Engl J Med 299 (25):  1412, 1978.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=152410&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Bashir Y, Tomson CR: Cardiac arrest  associated with hypokalaemia in a patient receiving mithramycin.  Postgrad Med J 64 (749): 228-9, 1988.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=2971935&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Ahr DJ, Scialla SJ, Kimbali DB Jr:  Acquired platelet dysfunction following mithramycin therapy. Cancer 41  (2): 448-54, 1978.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=147132&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Margileth DA, Smith FE, Lane M:  Sudden arterial occlusion associated with mithramycin therapy. Cancer 31  (3): 708-12, 1973.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4266415&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Warrell RP Jr, Murphy WK, Schulman  P, et al.: A randomized double-blind study of gallium nitrate compared  with etidronate for acute control of cancer-related hypercalcemia. J  Clin Oncol 9 (8): 1467-75, 1991.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1906532&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Warrell RP Jr, Lovett D, Dilmanian  FA, et al.: Low-dose gallium nitrate for prevention of osteolysis in  myeloma: results of a pilot randomized study. J Clin Oncol 11 (12):  2443-50, 1993.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=8246033&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Mundy GR, Rick ME, Turcotte R, et  al.: Pathogenesis of hypercalcemia in lymphosarcoma cell leukemia. Role  of an osteoclast activating factor-like substance and a mechanism of  action for glucocorticoid therapy. Am J Med 65 (4): 600-6, 1978.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=707520&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Ralston SH, Fogelman I, Gardiner MD,  et al.: Relative contribution of humoral and metastatic factors to the  pathogenesis of hypercalcaemia in malignancy. Br Med J (Clin Res Ed) 288  (6428): 1405-8, 1984.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6426577&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Potts JT: Diseases of the  parathyroid gland and other hyper- and hypocalcemic disorders. In:  Isselbacher KJ, Braunwald E, Wilson JD, et al., eds.: Principles of  Internal Medicine. New York: McGraw-Hill, 1994, pp. 2151-71.  			<br />

</li>

<li><a></a>Massry SG, Mueller E, Silverman AG,  et al.: Inorganic phosphate treatment of hypercalcemia. Arch Intern Med  121 (4): 307-12, 1968.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=5645701&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Hebert LA, Lemann J Jr, Petersen JR,  et al.: Studies of the mechanism by which phosphate infusion lowers  serum calcium concentration. J Clin Invest 45 (12): 1886-94, 1966.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=5953818&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Shackney S, Hasson J: Precipitous  fall in serum calcium, hypotension, and acute renal failure after  intravenous phosphate therapy for hypercalcemia. Report of two cases.  Ann Intern Med 66 (5): 906-16, 1967.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6025231&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Goldsmith RS, Ingbar SH: Inorganic  phosphate treatment of hypercalcemia of diverse etiologies. N Engl J Med  274 (1): 1-7, 1966.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=5901867&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Nolph KD, Stoltz M, Maher JF:  Calcium free peritoneal dialysis. Treatment of vitamin D intoxication.  Arch Intern Med 128 (5): 809-14, 1971.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=5315802&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Cardella CJ, Birkin BL, Rapoport A:  Role of dialysis in the treatment of severe hypercalcemia: report of two  cases successfully treated with hemodialysis and review of the  literature. Clin Nephrol 12 (6): 285-90, 1979.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=160852&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Schreiner GE, Teehan BP: Dialysis of  poisons and drugs - annual review. Trans Am Soc Artif Intern Organs 18  (0): 563-99, 1972.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=4610970&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Stoltz ML, Nolph KD, Maher JF:  Factors affecting calcium removal with calcium-free peritoneal dialysis.  J Lab Clin Med 78 (3): 389-98, 1971.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=5092860&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Seyberth HW, Segre GV, Morgan JL, et  al.: Prostaglandins as mediators of hypercalcemia associated with  certain types of cancer. N Engl J Med 293 (25): 1278-83, 1975.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1186822&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Seyberth HW, Segre GV, Hamet P, et  al.: Characterization of the group of patients with the hypercalcemia of  cancer who respond to treatment with prostaglandin synthesis  inhibitors. Trans Assoc Am Physicians 89: 92-104, 1976.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=190750&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Brenner DE, Harvey HA, Lipton A, et  al.: A study of prostaglandin E2, parathormone, and response to  indomethacin in patients with hypercalcemia of malignancy. Cancer 49  (3): 556-61, 1982.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7059914&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Coombes RC, Neville AM, Bondy PK, et  al.: Failure of indomethacin to reduce hypercalcemia in patients with  breast cancer. Prostaglandins 12 (6): 1027-35, 1976.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1005735&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Lad TE, Mishoulam HM, Shevrin DH, et  al.: Treatment of cancer-associated hypercalcemia with cisplatin. Arch  Intern Med 147 (2): 329-32, 1987.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3813752&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>List A: Malignant hypercalcemia. The  choice of therapy. Arch Intern Med 151 (3): 437-8, 1991.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1900408&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Warrell RP Jr, Israel R, Frisone M,  et al.: Gallium nitrate for acute treatment of cancer-related  hypercalcemia. A randomized, double-blind comparison to calcitonin. Ann  Intern Med 108 (5): 669-74, 1988.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3282463&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Blomqvist CP: Malignant  hypercalcemia--a hospital survey. Acta Med Scand 220 (5): 455-63, 1986.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=3812029&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Mundy GR, Martin TJ: The  hypercalcemia of malignancy: pathogenesis and management. Metabolism 31  (12): 1247-77, 1982.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=6755168&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

<li><a></a>Fisken RA, Heath DA, Bold AM:  Hypercalcaemia--a hospital survey. Q J Med 49 (196): 405-18, 1980  Autumn.  			<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7022540&dopt=Abstract"><span class="Summary-Citation-PUBMED"><span>[PUBMED Abstract]</span></span></a><br />

</li>

</ol><a></a>

<p><a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#top" class="backtotop-link"><img src="http://www.cancer.gov/images/backtotop_red.gif" alt="Back" width="13" height="14">Back to Top</a></p>

<p><span class="page-title"><a></a>Current Clinical Trials</span></p>

<p><a></a>   <a></a></p>

<p>Check NCI’s PDQ Cancer Clinical  Trials Registry for U.S. supportive and palliative care trials about  <a class="Protocol-ExternalRef" href="http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?Diagnosis=41391&tt=2&format=2&cn=1">hypercalcemia  of malignancy</a> that are now accepting  participants. The list of  trials can be further narrowed by location, drug, intervention, and  other criteria.</p>

<a></a>

<p>General information about clinical trials  is also available from the <a class="Protocol-ExternalRef" href="http://www.cancer.gov/clinicaltrials">NCI Web site</a>.</p>

<p><a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#top" class="backtotop-link"><img src="http://www.cancer.gov/images/backtotop_red.gif" alt="Back" width="13" height="14">Back to Top</a></p>

<p><span class="page-title"><a></a>Get More Information From NCI</span></p>

<p><a></a>   <a></a></p>

<p><i>       <b>Call 1-800-4-CANCER</b>     </i></p>

<a></a>

<p>For more information, U.S. residents may call  the National Cancer Institute's (NCI's) Cancer Information Service  toll-free at 1-800-4-CANCER (1-800-422-6237) Monday through Friday from  8:00 a.m. to 8:00 p.m., Eastern Time.  A trained Cancer Information  Specialist is available to answer your questions.</p>

<a></a>

<p><i>       <b>Chat online  </b>     </i></p>

<a></a>

<p>The <a class="Protocol-ExternalRef" href="https://cissecure.nci.nih.gov/livehelp/welcome.asp">NCI's  LiveHelp®</a> online chat service provides Internet users with the  ability to chat online with an Information Specialist. The service is  available from 8:00 a.m. to 11:00 p.m. Eastern time, Monday through  Friday. Information Specialists can help Internet users find information  on NCI Web sites and answer questions about cancer.</p>

<a></a>

<p><i>       <b>Write to us</b>     </i></p>

<a></a>

<p>For more information from the NCI, please write  to this address:</p>

<a></a>   <a></a>

<dl><dd>NCI Public Inquiries Office</dd>

<dd>Suite 3036A</dd>

<dd>6116 Executive Boulevard, MSC8322</dd>

<dd>Bethesda, MD 20892-8322</dd>

</dl><a></a>   <a></a>

<p><i>       <b>Search the NCI Web site</b>     </i></p>

<a></a>

<p>The <a class="Protocol-ExternalRef" href="http://cancer.gov/">NCI Web site</a> provides online access to  information on cancer, clinical trials, and other Web sites and  organizations that offer support and resources for cancer patients and  their families.  For a quick search, use the search box in the upper  right corner of each Web page. The results for a wide range of search  terms will include a list of "Best Bets," editorially chosen Web pages  that are most closely related to the search term entered.</p>

<a></a>

<p>There are also many other places to get  materials and information about cancer treatment and services.       Hospitals in your area may have information about  local and regional  agencies that have information on finances, getting to and from  treatment, receiving care at home, and dealing with problems related to  cancer treatment.</p>

<a></a>

<p><i>       <b>Find Publications</b>     </i></p>

<a></a>

<p>The NCI has booklets and other materials for  patients, health professionals, and the public.  These publications  discuss types of cancer, methods of cancer treatment, coping with  cancer, and clinical trials.  Some publications provide information on  tests for cancer, cancer causes and prevention, cancer statistics, and  NCI research activities.  NCI materials on these and other topics may be  ordered online or printed directly from the <a class="Protocol-ExternalRef" href="https://cissecure.nci.nih.gov/ncipubs">NCI Publications Locator</a>.  These materials can also be ordered by telephone from the Cancer  Information Service toll-free at 1-800-4-CANCER (1-800-422-6237).</p>

<p><a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#top" class="backtotop-link"><img src="http://www.cancer.gov/images/backtotop_red.gif" alt="Back" width="13" height="14">Back to Top</a></p>

<p><span class="page-title"><a></a>Changes to This Summary (04/13/2010)</span></p>

<p><a></a>   <a></a></p>

<p>The PDQ cancer information summaries are reviewed  regularly and updated as new information becomes available.  This  section describes the latest changes made to this summary as of the date  above.</p>

<a></a>

<p>Added level-of-evidence designations to some reference  citations in this summary to help readers assess the strength of the <a class="SummaryRef" href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/HealthProfessional/179.cdr#Section_179">evidence</a>  supporting the use of specific interventions or approaches.</p>

<p><a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#top" class="backtotop-link"><img src="http://www.cancer.gov/images/backtotop_red.gif" alt="Back" width="13" height="14">Back to Top</a></p>

<p><span class="page-title"><a></a>Questions or Comments About This Summary</span></p>

<p><a></a>   <a></a></p>

<p>If you have questions or comments about  this summary, please send them to Cancer.gov through the Web site’s <a class="Protocol-ExternalRef" href="http://cancer.gov/contact/form_contact.aspx">Contact Form</a>. We  can respond only to email messages written in English.</p>

<p><a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#top" class="backtotop-link"><img src="http://www.cancer.gov/images/backtotop_red.gif" alt="Back" width="13" height="14">Back to Top</a></p>

<p><span class="page-title"><a></a>More Information</span></p>

<p><a></a>   <a></a></p>

<p><b>About PDQ</b></p>

<a></a>   <a></a>

<ul class="Protocol-UL"><li class="Protocol-IL-Bullet"><a class="Protocol-ExternalRef" href="http://cancer.gov/cancerinfo/pdq/cancerdatabase">PDQ® - NCI's  Comprehensive Cancer Database</a>.<a></a><a></a>

<dl><dd>Full description  of the NCI PDQ database.</dd>

</dl><a></a></li>

</ul><a></a>   <a></a>

<p><b>Additional PDQ Summaries</b></p>

<a></a>   <a></a>

<ul class="Protocol-UL"><li class="Protocol-IL-Bullet"><a class="Protocol-ExternalRef" href="http://cancer.gov/cancerinfo/pdq/adulttreatment">PDQ® Cancer  Information Summaries: Adult Treatment</a>       <a></a>       <a></a>

<dl><dd>Treatment options for adult cancers.</dd>

</dl><a></a></li>

<li class="Protocol-IL-Bullet"><a class="Protocol-ExternalRef" href="http://cancer.gov/cancerinfo/pdq/pediatrictreatment">PDQ® Cancer  Information Summaries: Pediatric Treatment</a>       <a></a>       <a></a>

<dl><dd>Treatment options for childhood cancers.    </dd>

</dl><a></a></li>

<li class="Protocol-IL-Bullet"><a class="Protocol-ExternalRef" href="http://cancer.gov/cancerinfo/pdq/supportivecare">PDQ® Cancer  Information Summaries: Supportive and Palliative Care</a>       <a></a>       <a></a>

<dl><dd>Side effects of cancer treatment, management of  cancer-related complications and  pain, and psychosocial concerns.  </dd>

</dl><a></a></li>

<li class="Protocol-IL-Bullet"><a class="Protocol-ExternalRef" href="http://cancer.gov/cancerinfo/pdq/screening">PDQ® Cancer  Information Summaries: Screening/Detection (Testing for Cancer)</a>       <a></a>       <a></a>

<dl><dd>Tests or procedures that detect specific types of cancer.    </dd>

</dl><a></a></li>

<li class="Protocol-IL-Bullet"><a class="Protocol-ExternalRef" href="http://cancer.gov/cancerinfo/pdq/prevention">PDQ® Cancer  Information Summaries: Prevention </a>       <a></a>       <a></a>

<dl><dd>Risk factors and methods to increase chances of preventing  specific types of cancer.</dd>

</dl><a></a></li>

<li class="Protocol-IL-Bullet"><a class="Protocol-ExternalRef" href="http://cancer.gov/cancerinfo/pdq/genetics">PDQ® Cancer Information  Summaries: Genetics </a>       <a></a>       <a></a>

<dl><dd>Genetics of specific cancers and inherited cancer syndromes,  and ethical, legal, and social concerns.</dd>

</dl><a></a></li>

<li class="Protocol-IL-Bullet"><a class="Protocol-ExternalRef" href="http://cancer.gov/cancerinfo/pdq/cam">PDQ® Cancer Information  Summaries: Complementary and Alternative Medicine </a>       <a></a>       <a></a>

<dl><dd>Information about complementary and alternative forms of  treatment for patients with cancer.</dd>

</dl><a></a></li>

</ul><a></a>   <a></a>

<p><b>Important:</b></p>

<a></a>

<p>This information is intended mainly for use by doctors and other health  care professionals. If you have questions about this topic, you can ask  your doctor, or call the Cancer Information Service at <b>1-800-4-CANCER  (1-800-422-6237)</b>.</p>

<p><a href="http://www.cancer.gov/cancertopics/pdq/supportivecare/hypercalcemia/healthprofessional/allpages#top" class="backtotop-link"><img src="http://www.cancer.gov/images/backtotop_red.gif" alt="Back" width="13" height="14">Back to Top</a></p>

<img src="http://www.cancer.gov/images/spacer.gif" alt="image" width="10" height="1">

<img src="http://www.cancer.gov/images/spacer.gif" alt="image" width="1" height="30">